1,4-Butanediol

Sources

14 strong · 19 moderate · 10 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked

143

67verified29partial43inconclusive4not supported

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated

May 9, 2026 · pipeline-v5

Values approved

113/113 (100%)

Data points an editor reviewed and accepted for publication.

Value Provenance

Dosing

oraltrace

Field	Published	AI Proposed	Confidence
Threshold	0.5 mL	0.5 mL	low
Low	0.5–1 mL	0.5–1 mL	low
Common	1–2.5 mL	1–2.5 mL	low
Strong	2.5–4 mL	2.5–4 mL	low
Heavy	4+ mL	4+ mL	low
Editorial	Existing DB values (community consensus). Thai 2007 used 25 mg/kg ≈ 1.7 mL (common range) producing mild cognitive effects, broadly consistent with these ranges but not a formal validation. No controlled human dose-ranging study exists across the recreational spectrum. Volumetric dosing (mL) approximates mass (g) due to near-unit density (~1.0 g/mL). ADH1B genotype creates up to 4× variability in conversion rate, meaning effective dose varies dramatically between individuals.
	ReasoningReasoning Existing DB values (community consensus). Thai 2007 used 25 mg/kg ≈ 1.7 mL (common range) producing mild cognitive effects, broadly consistent with these ranges but not a formal validation. No controlled human dose-ranging study exists across the recreational spectrum. Volumetric dosing (mL) approximates mass (g) due to near-unit density (~1.0 g/mL). ADH1B genotype creates up to 4× variability in conversion rate, meaning effective dose varies dramatically between individuals. Evidence basis: community_consensus_large

Duration

oral

Field	Published	AI Proposed	Confidence
Onsettrace	20–60 minutes	20–60 minutes	medium
Editorial	Existing DB values consistent with literature: Thai 2007 (GHB metabolite Tmax 39 min), Schep 2012 (onset 30–60 min). Slower than GHB (15–30 min) and GBL (10–20 min) due to rate-limiting ADH conversion.
	ReasoningReasoning Existing DB values consistent with literature: Thai 2007 (GHB metabolite Tmax 39 min), Schep 2012 (onset 30–60 min). Slower than GHB (15–30 min) and GBL (10–20 min) due to rate-limiting ADH conversion. Evidence basis: community_consensus_large
Peaktrace	1–2 hours	1–2 hours	medium
Editorial	Existing DB values. Consistent with Carter 2003 demonstration that 1,4-BD has longer duration than GHB, and with sustained ADH-mediated conversion maintaining GHB plasma levels.
	ReasoningReasoning Existing DB values. Consistent with Carter 2003 demonstration that 1,4-BD has longer duration than GHB, and with sustained ADH-mediated conversion maintaining GHB plasma levels. Evidence basis: community_consensus_large
Offsettrace	1.5–2 hours	1.5–2 hours	medium
Editorial	Existing DB values. Consistent with GHB elimination half-life of ~32 min (Thai 2007) and clinical accounts of gradual resolution over 1.5–2 hours after peak.
	ReasoningReasoning Existing DB values. Consistent with GHB elimination half-life of ~32 min (Thai 2007) and clinical accounts of gradual resolution over 1.5–2 hours after peak. Evidence basis: community_consensus_large
Totaltrace	3–5 hours	3–5 hours	medium
Editorial	Existing DB values. Carter 2003 confirms longer duration vs GHB (2–4 h). Total range of 3–5 h is consistent with the slower conversion kinetics extending the overall experience window.
	ReasoningReasoning Existing DB values. Carter 2003 confirms longer duration vs GHB (2–4 h). Total range of 3–5 h is consistent with the slower conversion kinetics extending the overall experience window. Evidence basis: community_consensus_large
After effectstrace	2–4 hours	2–4 hours	medium
Editorial	Existing DB values. Residual drowsiness, cognitive fog, and impairment may persist 2–4 hours after primary effects resolve. No controlled data on aftereffects duration specifically.
	ReasoningReasoning Existing DB values. Residual drowsiness, cognitive fog, and impairment may persist 2–4 hours after primary effects resolve. No controlled data on aftereffects duration specifically. Evidence basis: community_consensus_large

Safety

Toxicity Profiletrace

Field	Published	AI Proposed	Confidence
Acute	high	high	medium
Chronic	moderate	moderate	medium
Organs Affected	CNS, pulmonary, neurological	CNS, pulmonary, neurological	medium
Editorial	Acute toxicity rated high based on steep dose-response curve, documented fatalities (Caldicott 2004, Simonsen 2015), and narrow therapeutic window (Busardò & Jones 2014). Chronic toxicity rated moderate based on animal oxidative stress data (Sgaravatti 2009) and human cognitive impairment in chronic users (Amsterdam 2022), but no structural neuroimaging or long-term outcome studies exist.
	ReasoningReasoning Acute toxicity rated high based on steep dose-response curve, documented fatalities (Caldicott 2004, Simonsen 2015), and narrow therapeutic window (Busardò & Jones 2014). Chronic toxicity rated moderate based on animal oxidative stress data (Sgaravatti 2009) and human cognitive impairment in chronic users (Amsterdam 2022), but no structural neuroimaging or long-term outcome studies exist. Evidence basis: published_case_series

Dependence Profiletrace

Field	Published	AI Proposed	Confidence
Physical	high	high	high
Psychological	high	high	high
Compulsive Redosing	high	high	high
Dose Escalation	moderate	moderate	high
Editorial	High physical and psychological dependence well-documented in Brunt et al. 2014, Kamal et al. 2016. Compulsive redosing (every 1–3 hours) and withdrawal severity consistently reported. Dutch treatment admissions data confirms population-level dependence burden. Reinforcement mechanism via mesolimbic dopamine established in Tunnicliff 1992 and Kamal 2016.
	ReasoningReasoning High physical and psychological dependence well-documented in Brunt et al. 2014, Kamal et al. 2016. Compulsive redosing (every 1–3 hours) and withdrawal severity consistently reported. Dutch treatment admissions data confirms population-level dependence burden. Reinforcement mechanism via mesolimbic dopamine established in Tunnicliff 1992 and Kamal 2016. Evidence basis: published_case_series

Withdrawal Profiletrace

Field	Published	AI Proposed	Confidence
Severity	life_threatening	life_threatening	high
Symptoms	anxiety, agitation, insomnia, tremors, tachycardia, hypertension, auditory hallucinations, visual hallucinations, profuse sweating, delirium, seizures, rhabdomyolysis	anxiety, agitation, insomnia, tremors, tachycardia, hypertension, auditory hallucinations, visual hallucinations, profuse sweating, delirium, seizures, rhabdomyolysis	high
Fatal	Yes	Yes	high
Medical Supervision	Required	Required	high
Editorial	Withdrawal comparable to alcohol/benzodiazepine withdrawal but faster onset due to GHB half-life ~30 min. Documented in Schep 2012, Moitroux & Kestens 2023. One case documented recurrence over 56 days (Gupta 2025). Benzodiazepines show high treatment resistance. Life-threatening delirium and seizures documented.
	ReasoningReasoning Withdrawal comparable to alcohol/benzodiazepine withdrawal but faster onset due to GHB half-life ~30 min. Documented in Schep 2012, Moitroux & Kestens 2023. One case documented recurrence over 56 days (Gupta 2025). Benzodiazepines show high treatment resistance. Life-threatening delirium and seizures documented. Evidence basis: published_case_series

Tolerance Profiletrace

Field	Published	AI Proposed	Confidence
Buildup	moderate	moderate	low
Half-life	—	—	low
Full Reset	10.5 days	10.5 days	low
Cross-tolerances	baclofen	baclofen	low
Editorial	Buildup rate from clinical literature (Kamal 2016, Brunt 2014). GABA-B selectivity demonstrated by cross-tolerance to baclofen but not flunitrazepam (Kamal 2016). Full reset (10.5 days) from existing DB/community consensus — not confirmed in published literature, proposed with low confidence.
	ReasoningReasoning Buildup rate from clinical literature (Kamal 2016, Brunt 2014). GABA-B selectivity demonstrated by cross-tolerance to baclofen but not flunitrazepam (Kamal 2016). Full reset (10.5 days) from existing DB/community consensus — not confirmed in published literature, proposed with low confidence. Evidence basis: community_consensus_large

Effects & Profile

Contraindications

Field	Published	AI Proposed	Confidence
other Concurrent ethanol usetrace	absolute	absolute	high
Editorial	Dual mechanism documented in Poldrugo & Snead 1984, Lenz et al. 2011, Stefani & Roberts 2020. Multiple fatality case series (Caldicott 2004, Simonsen 2015) implicate ethanol co-ingestion.
	ReasoningReasoning Dual mechanism documented in Poldrugo & Snead 1984, Lenz et al. 2011, Stefani & Roberts 2020. Multiple fatality case series (Caldicott 2004, Simonsen 2015) implicate ethanol co-ingestion.
other Concurrent opioid usetrace	absolute	absolute	high
Editorial	Multiple fatalities documented in Caldicott et al. 2004 and Simonsen et al. 2015 involving GHB-precursor + opioid combinations.
	ReasoningReasoning Multiple fatalities documented in Caldicott et al. 2004 and Simonsen et al. 2015 involving GHB-precursor + opioid combinations.
other Concurrent benzodiazepine usetrace	absolute	absolute	high
Editorial	Documented in Devlin & Henry 2008, Doyno & White 2021. Additive CNS depression at intoxicating doses confirmed in clinical literature.
	ReasoningReasoning Documented in Devlin & Henry 2008, Doyno & White 2021. Additive CNS depression at intoxicating doses confirmed in clinical literature.
other Other sedative-hypnoticstrace	absolute	absolute	high
Editorial	Class-level additive CNS depression documented in Schep et al. 2012 and Devlin & Henry 2008.
	ReasoningReasoning Class-level additive CNS depression documented in Schep et al. 2012 and Devlin & Henry 2008.
respiratory Respiratory conditionstrace	absolute	absolute	high
Editorial	Respiratory depression is the primary cause of GHB-related death, documented across Schep et al. 2012 and Mégarbane et al. 2020. Pre-existing insufficiency compounds this risk.
	ReasoningReasoning Respiratory depression is the primary cause of GHB-related death, documented across Schep et al. 2012 and Mégarbane et al. 2020. Pre-existing insufficiency compounds this risk.
other Operating vehicles or machinerytrace	absolute	absolute	high
Editorial	Motor impairment, sedation, and amnesia consistently documented across clinical literature (Thai 2007, Schep 2012).
	ReasoningReasoning Motor impairment, sedation, and amnesia consistently documented across clinical literature (Thai 2007, Schep 2012).
neurological Epilepsy or seizure historytrace	relative	relative	medium
Editorial	Withdrawal seizures documented in Schep et al. 2012 and Borelli et al. 2025. Seizure threshold modulation is a known GHB pharmacological property.
	ReasoningReasoning Withdrawal seizures documented in Schep et al. 2012 and Borelli et al. 2025. Seizure threshold modulation is a known GHB pharmacological property.
metabolic ADH1B variant carrierstrace	relative	relative	medium
Editorial	Thai et al. 2007 demonstrated 4× difference in CL/F between ADH1B variant and wild-type subjects (p=0.061). Genetically mediated vulnerability to unpredictable pharmacokinetics.
	ReasoningReasoning Thai et al. 2007 demonstrated 4× difference in CL/F between ADH1B variant and wild-type subjects (p=0.061). Genetically mediated vulnerability to unpredictable pharmacokinetics.
pregnancy breastfeeding Pregnancytrace	relative	relative	low
Editorial	Complete absence of reproductive safety data. Flagged as safety-citation-needed in article prose.
	ReasoningReasoning Complete absence of reproductive safety data. Flagged as safety-citation-needed in article prose.
other NSAID use (diclofenac)trace	relative	relative	low
Editorial	Rodriguez-Cruz et al. 2021 demonstrated MCT1 inhibition by diclofenac reducing brain GHB concentrations in rats. Clinical significance in humans not established.
	ReasoningReasoning Rodriguez-Cruz et al. 2021 demonstrated MCT1 inhibition by diclofenac reducing brain GHB concentrations in rats. Clinical significance in humans not established.

Timeline Phases

oral

Field	Published	AI Proposed	Confidence
Onsettrace	0–1800 sec(i=0.10)	0–1800 sec(i=0.10)	medium
Editorial	Timeline derived from existing DB duration data (onset 20–60 min, peak 1–2 h, offset 1.5–2 h, total 3–5 h, aftereffects 2–4 h), consistent with published literature: Thai 2007 (Tmax 39 min for GHB metabolite), Carter 2003 (longer duration vs GHB), Schep 2012 (onset 30–60 min). No controlled human dose-ranging study at recreational doses confirms these phases directly.
	ReasoningReasoning Timeline derived from existing DB duration data (onset 20–60 min, peak 1–2 h, offset 1.5–2 h, total 3–5 h, aftereffects 2–4 h), consistent with published literature: Thai 2007 (Tmax 39 min for GHB metabolite), Carter 2003 (longer duration vs GHB), Schep 2012 (onset 30–60 min). No controlled human dose-ranging study at recreational doses confirms these phases directly. Evidence basis: community_consensus_large
Come uptrace	1200–2700 sec(i=0.40)	1200–2700 sec(i=0.40)	medium
Editorial	Timeline derived from existing DB duration data (onset 20–60 min, peak 1–2 h, offset 1.5–2 h, total 3–5 h, aftereffects 2–4 h), consistent with published literature: Thai 2007 (Tmax 39 min for GHB metabolite), Carter 2003 (longer duration vs GHB), Schep 2012 (onset 30–60 min). No controlled human dose-ranging study at recreational doses confirms these phases directly.
	ReasoningReasoning Timeline derived from existing DB duration data (onset 20–60 min, peak 1–2 h, offset 1.5–2 h, total 3–5 h, aftereffects 2–4 h), consistent with published literature: Thai 2007 (Tmax 39 min for GHB metabolite), Carter 2003 (longer duration vs GHB), Schep 2012 (onset 30–60 min). No controlled human dose-ranging study at recreational doses confirms these phases directly. Evidence basis: community_consensus_large
Peaktrace	3600–7200 sec(i=1.00)	3600–7200 sec(i=1.00)	medium
Editorial	Timeline derived from existing DB duration data (onset 20–60 min, peak 1–2 h, offset 1.5–2 h, total 3–5 h, aftereffects 2–4 h), consistent with published literature: Thai 2007 (Tmax 39 min for GHB metabolite), Carter 2003 (longer duration vs GHB), Schep 2012 (onset 30–60 min). No controlled human dose-ranging study at recreational doses confirms these phases directly.
	ReasoningReasoning Timeline derived from existing DB duration data (onset 20–60 min, peak 1–2 h, offset 1.5–2 h, total 3–5 h, aftereffects 2–4 h), consistent with published literature: Thai 2007 (Tmax 39 min for GHB metabolite), Carter 2003 (longer duration vs GHB), Schep 2012 (onset 30–60 min). No controlled human dose-ranging study at recreational doses confirms these phases directly. Evidence basis: community_consensus_large
Resolutiontrace	5400–7200 sec(i=0.50)	5400–7200 sec(i=0.50)	medium
Editorial	Timeline derived from existing DB duration data (onset 20–60 min, peak 1–2 h, offset 1.5–2 h, total 3–5 h, aftereffects 2–4 h), consistent with published literature: Thai 2007 (Tmax 39 min for GHB metabolite), Carter 2003 (longer duration vs GHB), Schep 2012 (onset 30–60 min). No controlled human dose-ranging study at recreational doses confirms these phases directly.
	ReasoningReasoning Timeline derived from existing DB duration data (onset 20–60 min, peak 1–2 h, offset 1.5–2 h, total 3–5 h, aftereffects 2–4 h), consistent with published literature: Thai 2007 (Tmax 39 min for GHB metabolite), Carter 2003 (longer duration vs GHB), Schep 2012 (onset 30–60 min). No controlled human dose-ranging study at recreational doses confirms these phases directly. Evidence basis: community_consensus_large
Afterglowtrace	7200–14400 sec(i=0.15)	7200–14400 sec(i=0.15)	medium
Editorial	Timeline derived from existing DB duration data (onset 20–60 min, peak 1–2 h, offset 1.5–2 h, total 3–5 h, aftereffects 2–4 h), consistent with published literature: Thai 2007 (Tmax 39 min for GHB metabolite), Carter 2003 (longer duration vs GHB), Schep 2012 (onset 30–60 min). No controlled human dose-ranging study at recreational doses confirms these phases directly.
	ReasoningReasoning Timeline derived from existing DB duration data (onset 20–60 min, peak 1–2 h, offset 1.5–2 h, total 3–5 h, aftereffects 2–4 h), consistent with published literature: Thai 2007 (Tmax 39 min for GHB metabolite), Carter 2003 (longer duration vs GHB), Schep 2012 (onset 30–60 min). No controlled human dose-ranging study at recreational doses confirms these phases directly. Evidence basis: community_consensus_large

Dose Tier Summaries

thresholdtrace

low

Sub-perceptual or barely perceptible effects emerge as faint warmth, mild lightheadedness, or a subtle shift in body awareness. Most users report uncertainty about whether effects are genuinely present or placebo. The experience may register only as a slight loosening of baseline tension. Physically, threshold doses produce no significant motor control impairment, no measurable sedation, and no changes in heart rate or respiration. Dehydration sensation may occur as a faint dryness. Functional capacity is fully preserved. The slow ADH-mediated conversion means even this faint signal may take 30–60 minutes to appear. Individual variation in ADH1B genotype can shift thresholds substantially between users.

Editorial

No controlled human data at threshold doses. Thai 2007 used 25 mg/kg (~1.7 mL, common range) and reported only mild effects, suggesting threshold is well below this. Descriptions extrapolated from GHB community consensus and pharmacological reasoning about sub-effective GHB plasma concentrations.

Reasoning

Evidence basis: community_consensus_large

lighttrace

low

Gentle relaxation and mild euphoria emerge, comparable in intensity to one or two alcoholic drinks. Anxiety suppression becomes noticeable as social situations feel easier and conversation flows more freely. A light body high and warmth spread through the torso and limbs. Physical effects are subtle: mild muscle relaxation, slight stimulation at the lower end of this range giving way to relaxation at the upper end. Motor control is minimally affected. Nausea is uncommon. Heart rate and breathing remain essentially normal. This range represents the lowest reliably psychoactive dose. The slow onset (30–60 minutes) tempts redosing — a significant risk given the steep dose-response curve. Users should wait at least 90 minutes before considering any adjustment.

Editorial

Community consensus dose ranges. Thai 2007 at 25 mg/kg (~1.7 mL) produced mild cognitive effects consistent with the upper boundary of this tier. Subjective descriptions inferred from GHB community literature.

Reasoning

Evidence basis: community_consensus_large

commontrace

medium

Clear euphoria, disinhibition, and enhanced sociability define this range. Music enhancement becomes apparent, sexual arousal enhancement is frequently reported, and cognitive euphoria produces a warm, contented mental state. Communication feels effortless and empathy enhancement may emerge. Laughter fits occur in social settings. Motor control impairment becomes noticeable — coordination is visibly affected. Amnesia may begin, particularly at the upper boundary. Body high intensifies. Nausea occurs in some users. Thought deceleration and analysis suppression produce a cognitively relaxed state. Stimulation gives way to sedation as doses approach the upper end. This range corresponds to the 25 mg/kg dose used in Thai 2007 (~1.7 mL). The steep dose-response curve means small increments above this range can produce disproportionate intensification. Volumetric dosing (mL) approximates mass dosing (g) due to near-unit density.

Editorial

Thai 2007 (25 mg/kg ≈ 1.7 mL) falls within this range and produced measurable cognitive and physiological effects. Effect profile at this tier synthesized from GHB clinical reviews (Schep 2012, Busardò & Jones 2014) and community consensus.

Reasoning

Evidence basis: community_consensus_large

strongtrace

low

Pronounced sedation dominates the experience. Euphoria may persist but is increasingly overshadowed by cognitive impairment and drowsiness. Substantial amnesia develops — users may lose memory of extended periods. Speech becomes slurred, and confusion increases. Delusions of sobriety may lead to dangerous misjudgment of impairment level. Motor control impairment is significant — walking becomes unsteady, fine motor tasks are difficult. Nausea and vomiting risk increase. Respiratory depression becomes clinically relevant, with measurable decreases in respiratory rate and oxygen saturation. Loss of consciousness is possible, particularly at the upper boundary. This range approaches the territory where the five-fold gap between euphoric (~100 mg/L) and potentially fatal (~500 mg/L) plasma GHB concentrations becomes critically relevant. ADH1B genotype variability means some individuals reach dangerous GHB levels within this dose range.

Editorial

No controlled human data at strong doses. Dose boundaries from community consensus. Clinical features synthesized from GHB overdose presentations in Schep 2012 and Busardò & Jones 2014. The steep concentration-effect curve is well-documented.

Reasoning

Evidence basis: community_consensus_large

heavytrace

low

High risk of unconsciousness and respiratory depression requiring medical intervention. Users at this dose level may become completely unresponsive, with depressed breathing, bradycardia, and hypothermia. Vomiting while unconscious creates life-threatening aspiration risk. Myoclonus (involuntary body movements) may be present. Respiratory depression can progress to respiratory arrest without intervention. The narrow margin between sedation and fatal cardiorespiratory depression is effectively exhausted at this range. Recovery from uncomplicated episodes typically occurs within 2–6 hours with supportive care, but polysubstance involvement dramatically worsens outcomes. This dose range is potentially fatal, especially with any concurrent CNS depressant use. Ethanol co-ingestion is particularly treacherous due to the dual ADH-competition mechanism that can produce delayed GHB surges. Emergency medical assistance should be immediately accessible.

Editorial

No controlled human data at heavy doses. Clinical features from GHB overdose case series (Schep 2012, Mégarbane 2020, Stefani & Roberts 2020). Dose boundary (4+ mL) from community consensus only.

Reasoning

No controlled human data at heavy doses. Clinical features from GHB overdose case series (Schep 2012, Mégarbane 2020, Stefani & Roberts 2020). Dose boundary (4+ mL) from community consensus only.

Evidence basis: community_consensus_large

History

current version

published Jun 4, 2026AI-generated—

versions

1 total

publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correction contact@psychedex.org

Sources

14 strong · 19 moderate · 10 weak

[1]
moderate
Binding characteristics of gamma-hydroxybutyric acid as a weak but selective GABAB receptor agonist
Mathivet P, Bernasconi R, De Barry J, et al. · 1997 · European Journal of Pharmacology
pubmed 90837883 claims checked1 verified2 partial
[2]
moderate
Gamma-hydroxybutyrate is a weak agonist at recombinant GABA(B) receptors
Lingenhoehl K, Brom R, Heid J, et al. · 1999 · Neuropharmacology
pubmed 105870823 claims checked3 verified
[3]
moderate
1,4 Butanediol, gamma-hydroxybutyric acid and ethanol: relationships and interactions
Poldrugo F, Snead OC · 1984 · Neuropharmacology
pubmed 67177524 claims checked3 verified1 inconclusive
[4]
moderate
The Xyrem risk management program
Fuller DE, Hornfeldt CS, Kelloway JS, Stahl PJ, Anderson TF · 2004 · Drug Safety
pubmed 150616843 claims checked2 verified1 partial
[5]
strong
GHB, GBL and 1,4-BD addiction
Brunt TM, van Amsterdam JG, van den Brink W · 2014 · Current Pharmaceutical Design
pubmed 240012909 claims checked1 verified7 inconclusive1 not supported
[6]
moderate
Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse
Tay E, Lo WKW, Murnion B · 2022 · Substance Abuse and Rehabilitation
doi.org/10.2147/sar.s315720 pubmed 351735152 claims checked2 inconclusive
[7]
strong
GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome
Busardò FP, Jones AW · 2015 · Current Neuropharmacology
doi.org/10.2174/1570159x13666141210215423 pubmed 260747435 claims checked4 verified1 partial
[8]
strong
Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers
Thai D, Dyer JE, Jacob P, Haller CA · 2007 · Clinical Pharmacology and Therapeutics
pubmed 1719277112 claims checked2 verified5 partial5 inconclusive
[9]
strong
Specific gamma-hydroxybutyrate-binding sites but loss of pharmacological effects of gamma-hydroxybutyrate in GABA(B)(1)-deficient mice
Kaupmann K, Cryan JF, Wellendorph P, et al. · 2003 · European Journal of Neuroscience
pubmed 146563213 claims checked3 verified
[10]
moderate
The role of GABAB receptors in the discriminative stimulus effects of gamma-hydroxybutyrate in rats: time course and antagonism studies
Carter LP, Flores LR, Wu H, et al. · 2003 · Journal of Pharmacology and Experimental Therapeutics
pubmed 126066394 claims checked3 verified1 partial
[11]
moderate
Significance of gamma-hydroxybutyric acid in the brain
Tunnicliff G · 1992 · General Pharmacology
pubmed 14871124 claims checked1 verified1 partial1 inconclusive1 not supported
[12]
weak
1,4-Butanediol overdose mimicking toxic alcohol exposure
Stefani M, Roberts DM · 2020 · Clinical Toxicology
doi.org/10.1080/15563650.2019.1617419 pubmed 312188927 claims checked4 verified2 partial1 inconclusive
[13]
moderate
The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol
Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Megarbane B · 2012 · Clinical Toxicology
doi.org/10.3109/15563650.2012.702218 pubmed 2274638311 claims checked11 inconclusive
[14]
weak
Gamma hydroxybutirate use for sexual assault
Varela M · 2004 · Emergency Medicine Journal
doi.org/10.1136/emj.2002.002402 pubmed 149883712 claims checked2 verified
[15]
strong
The Neurobiological Mechanisms of Gamma-Hydroxybutyrate Dependence and Withdrawal and Their Clinical Relevance: A Review
Kamal RM, van Noorden MS, Franzek E, Dijkstra BAG, Loonen AJM · 2016 · Neuropsychobiology
doi.org/10.1159/000443173 pubmed 270031769 claims checked3 verified1 partial4 inconclusive1 not supported
[16]
moderate
Fatalities associated with the use of gamma-hydroxybutyrate and its analogues in Australasia
Caldicott DG, Chow FY, Burns BJ, Felgate PD, Byard RW · 2004 · Medical Journal of Australia
pubmed 153772407 claims checked1 verified1 partial5 inconclusive
[17]
moderate
Fatal poisoning in drug addicts in the Nordic countries in 2012
Simonsen KW, Edvardsen HM, Thelander G, et al. · 2015 · Forensic Science International
doi.org/10.1016/j.forsciint.2015.01.003 pubmed 256451325 claims checked2 verified3 partial
[18]
strong
γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology
Felmlee MA, Morse BL, Morris ME · 2021 · The AAPS Journal
doi.org/10.1208/s12248-020-00543-z pubmed 334170722 claims checked2 inconclusive
[19]
moderate
Inhibition of 1,4-butanediol metabolism in human liver in vitro
Lenz D, Jübner M, Bender K, et al. · 2011 · Naunyn-Schmiedeberg's Archives of Pharmacology
doi.org/10.1007/s00210-011-0627-9 pubmed 215339965 claims checked3 verified2 partial
[20]
strong
Butanediol Conversion to Gamma-Hydroxybutyrate Markedly Reduced by the Alcohol Dehydrogenase Blocker Fomepizole
Liakoni E, Gugelmann H, Dempsey DA, et al. · 2019 · Clinical Pharmacology and Therapeutics
doi.org/10.1002/cpt.1306 pubmed 304506423 claims checked3 verified
[21]
moderate
Role of GABA(B) receptors in the sedative/hypnotic effect of gamma-hydroxybutyric acid
Carai MA, Colombo G, Brunetti G, et al. · 2001 · European Journal of Pharmacology
pubmed 116891893 claims checked1 verified2 partial
[22]
moderate
The Discriminative stimulus effects of gamma-hydroxybutyrate and related compounds in rats discriminating baclofen or diazepam
Carter LP, Unzeitig AW, Wu H, et al. · 2004 · Journal of Pharmacology and Experimental Therapeutics
pubmed 147427393 claims checked3 verified
[23]
moderate
Evidence for a G protein-coupled gamma-hydroxybutyric acid receptor
Snead OC · 2000 · Journal of Neurochemistry
pubmed 110328882 claims checked1 verified1 partial
[24]
strong
GHB (gamma-hydroxybutyrate) carrier-mediated transport across the blood-brain barrier
Bhattacharya I, Boje KM · 2004 · Journal of Pharmacology and Experimental Therapeutics
pubmed 151733141 claim checked1 verified
[25]
moderate
The distribution of gamma-hydroxybutyrate-induced Fos expression in rat brain: comparison with baclofen
van Nieuwenhuijzen PS, McGregor IS, Hunt GE · 2009 · Neuroscience
doi.org/10.1016/j.neuroscience.2008.10.011 pubmed 189964473 claims checked3 verified
[26]
moderate
Effects of 1,4-butanediol administration on oxidative stress in rat brain: study of the neurotoxicity of GHB in vivo
Sgaravatti AM, Magnusson AS, Oliveira AS, et al. · 2009 · Metabolic Brain Disease
pubmed 192962102 claims checked2 verified
[27]
strong
Cognitive Impairment Following Clinical or Recreational Use of Gammahydroxybutyric Acid (GHB): A Systematic Review
Amsterdam JV, Brunt TM, Pereira FR, Crunelle CL, Brink WVD · 2022 · Current Neuropharmacology
doi.org/10.2174/1570159x19666210610094352 pubmed 341517663 claims checked1 verified2 inconclusive
[28]
moderate
Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects
Brenneisen R, ElSohly MA, Murphy TP, et al. · 2004 · Journal of Analytical Toxicology
pubmed 155389553 claims checked1 verified1 partial1 not supported
[29]
moderate
Drug-drug interaction between diclofenac and gamma-hydroxybutyric acid
Rodriguez-Cruz V, Ren T, Morris ME · 2021 · Biopharmaceutics & Drug Disposition
doi.org/10.1002/bdd.2296 pubmed 341913013 claims checked3 verified
[30]
strong
Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials
Boscolo-Berto R, Viel G, Montagnese S, et al. · 2012 · Sleep Medicine Reviews
doi.org/10.1016/j.smrv.2011.09.001 pubmed 22055895no claims checked
[31]
strong
Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology
Sinclair JM, Kalk NJ, Kaar SJ, et al. · 2026 · Journal of psychopharmacology
doi.org/10.1177/02698811251399593 pubmed 417319471 claim checked1 verified
[32]
weak
Baclofen and gamma-hydroxybutyrate withdrawal
LeTourneau JL, Hagg DS, Smith SM · 2008 · Neurocritical Care
doi.org/10.1007/s12028-008-9062-2 pubmed 182661112 claims checked2 partial
[33]
weak
Treatment of Poorly Responsive Gamma-Hydroxybutyrate Withdrawal With Baclofen: A Case Report
Lai W, Raposa JT, Parlapalli R · 2022 · Cureus
doi.org/10.7759/cureus.25728 pubmed 358126082 claims checked2 verified
[34]
strong
Management of pharmaceutical and recreational drug poisoning
Mégarbane B, Oberlin M, Alvarez JC, et al. · 2020 · Annals of Intensive Care
doi.org/10.1186/s13613-020-00762-9 pubmed 332265021 claim checked1 inconclusive
[35]
weak
Withdrawal syndrome following chronic use of gamma-hydroxybutyric acid (GHB)
Moitroux A, Kestens C · 2023 · Revue medicale de Liege
pubmed 375609601 claim checked1 partial
[36]
weak
Severe gamma-hydroxybutyrate withdrawal with delirium, hemodynamic lability, and rhabdomyolysis: A case series
Borelli CM, Kessler N, Suter D, Levesque A · 2025 · The American Journal on Addictions
doi.org/10.1111/ajad.70013 pubmed 399537041 claim checked1 verified
[37]
weak
A case of severe and prolonged gamma-hydroxybutyrate (GHB) withdrawal syndrome successfully managed with a slow benzodiazepine and baclofen taper
Gupta R, Moon G, Bonomo Y, Pastor A · 2025 · Drug and Alcohol Review
doi.org/10.1111/dar.13911 pubmed 390210431 claim checked1 partial
[38]
weak
Inpatient GHB withdrawal management in an inner-city hospital in Sydney, Australia: a retrospective medical record review
Siefried KJ, Freeman G, Roberts DM, et al. · 2023 · Psychopharmacology
doi.org/10.1007/s00213-022-06283-6 pubmed 365080551 claim checked1 inconclusive
[39]
weak
Phenobarbital to manage severe gamma-hydroxybutyrate withdrawal: A case series
Freeman G, Siefried KJ, Roberts DM, et al. · 2023 · Drug and Alcohol Review
doi.org/10.1111/dar.13556 pubmed 362690811 claim checked1 verified
[40]
strong
Clinical review: Major consequences of illicit drug consumption
Devlin RJ, Henry JA · 2008 · Critical Care
doi.org/10.1186/cc6166 pubmed 182795353 claims checked2 verified1 partial
[41]
strong
Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank
Doyno CR, White CM · 2021 · Journal of Clinical Pharmacology
doi.org/10.1002/jcph.1922 pubmed 343965512 claims checked2 verified
[42]
moderate
Chemsex and antiretroviral prescribing in an HIV cohort in Brighton, UK
Adler Z, Fitzpatrick C, Broadwell N, et al. · 2022 · HIV Medicine
doi.org/10.1111/hiv.13239 pubmed 350484901 claim checked1 verified
[43]
weak
Legal Status of 1,4-Butanediol: UK Misuse of Drugs Act (Class C, 2009), Federal Analogue Act (US), Australian border-controlled drug (2024)
Various government sources · 2024
linkno claims checked

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary12 claims3verified5partial4inconclusive

inconclusiveFirst identified as a GHB precursor in 1984, 1,4-BD emerged as a recreational substance when GHB was scheduled in the United States and Europe in the late 1990s^[3]70%

Inconclusive

Abstract establishes 1,4-BD effects are mediated by GHB (confirming precursor relationship) but contains no information about the 1984 identification date, GHB scheduling, or the recreational emergence narrative.

1,4-BD effects are mediated by GHB, and ethanol blocks conversion of 1,4-BD to GHB

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveIts dual status as a bulk industrial chemical and unscheduled GHB precursor has created persistent regulatory challenges^[5]75%

Inconclusive

Abstract covers addiction and toxicology of GHB and precursors but does not address regulatory challenges or industrial chemical status.

Review of neurochemistry, acute toxicity, addiction potential, withdrawal, and treatment of GHB and its precursors

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveThe only controlled human pharmacokinetic study was published in 2007.^[8]65%

Inconclusive

Abstract describes a human crossover PK study (n=8) but does not state a publication year or confirm it is the only such study.

Human crossover PK study (n=8). BD Tmax 24±12 min, T1/2 39.3±11 min

checked by claude-sonnet-4-6 · May 9, 2026

partialOnce converted to GHB, 1,4-butanediol exerts effects primarily through weak partial agonism at GABA-B receptors (Ki ≈ 100 µM, EC50 ≈ 5 mM achieving approximately 69% of maximal baclofen response)^[1]85%

Partial

Abstract confirms Ki ≈ 100 µM at GABA-B receptors, but EC50 ≈ 5 mM and the 69% maximal response figure are not present — those come from a separate study.

Ki values of GHB at GABA-B receptors ~100 microM across multiple radioligand assays

checked by claude-sonnet-4-6 · May 9, 2026

verifiedOnce converted to GHB, 1,4-butanediol exerts effects primarily through weak partial agonism at GABA-B receptors (Ki ≈ 100 µM, EC50 ≈ 5 mM achieving approximately 69% of maximal baclofen response)^[2]95%

Verified

Abstract directly confirms EC50 ~5 mM and maximal stimulation 69% vs L-baclofen, establishing GHB as a weak partial agonist at GABA-B.

GHB activates GABA-B receptors with EC50 ~5 mM and maximal stimulation 69% vs L-baclofen (partial agonist)

checked by claude-sonnet-4-6 · May 9, 2026

verifiedGABA-B1 knockout mice lose all GHB pharmacological effects while retaining GHB-specific binding sites, and GABA-B antagonists fully block sedation and discriminative stimulus effects^[9]97%

Verified

Abstract directly confirms GABA-B1 KO mice lose all studied GHB behavioral effects despite retaining GHB-specific binding sites.

GABA-B1 knockout mice lose all studied GHB behavioral effects despite retaining GHB-specific binding sites

checked by claude-sonnet-4-6 · May 9, 2026

partialGABA-B1 knockout mice lose all GHB pharmacological effects while retaining GHB-specific binding sites, and GABA-B antagonists fully block sedation and discriminative stimulus effects^[10]80%

Partial

Abstract confirms GABA-B antagonist CGP 35348 antagonized GHB and 1,4-BD effects (supporting the antagonist part), but says nothing about knockout mice retaining binding sites.

GABA-B antagonist CGP 35348 antagonized GHB and 1,4-BD effects

checked by claude-sonnet-4-6 · May 9, 2026

partialA distinct high-affinity GHB receptor (Kd ≈ 95 nM) may mediate prosocial and euphoric effects not shared by baclofen.^[11]80%

Partial

Abstract confirms two binding site affinities including Kd 95 nM, but does not address prosocial or euphoric effects — that functional claim is not supported by this receptor-binding review.

two GHB binding site affinities (Kd 95 nM and 16 microM)

checked by claude-sonnet-4-6 · May 9, 2026

partialADH1B genotype variants produce up to four-fold differences in conversion rate, and ethanol co-ingestion competitively inhibits ADH, causing delayed but potentially lethal GHB surges when ethanol clears^[8]75%

Partial

Abstract confirms ADH1B G143A variant is associated with slower metabolism, supporting genotype variability, but the specific 'four-fold' figure and the delayed-surge-when-ethanol-clears mechanism are not present.

ADH-IB G143A variant associated with slower metabolism

checked by claude-sonnet-4-6 · May 9, 2026

Partial

Abstract confirms ethanol interaction delayed GHB conversion and documents the highest reported 1,4-BD blood concentration (supporting accumulation risk), but does not address ADH1B genotype or the four-fold figure.

ethanol interaction delayed GHB conversion; highest reported 1,4-BD blood concentration in literature

checked by claude-sonnet-4-6 · May 9, 2026

inconclusivePhysical dependence develops within weeks of continuous use; withdrawal includes delirium, seizures, and rhabdomyolysis^[13]70%

Inconclusive

Abstract is a comprehensive toxicology review covering withdrawal, but the specific timeline ('weeks') and individual withdrawal features (delirium, seizures, rhabdomyolysis) are not in the abstract text.

Comprehensive review of GHB, GBL, and 1,4-BD toxicology including... clinical features, management, and withdrawal

checked by claude-sonnet-4-6 · May 9, 2026

verifiedPlasma GHB concentrations of approximately 100 mg/L produce euphoria while approximately 500 mg/L approach fatal cardiorespiratory depression, leaving minimal margin between desired effects and overdose.^[7]97%

Verified

Abstract directly states ~100 mg/L causes euphoria/disinhibition and ~500 mg/L can cause death.

~100 mg/L plasma GHB causes euphoria/disinhibition; ~500 mg/L can cause death

checked by claude-sonnet-4-6 · May 9, 2026

history9 claims3verified3partial1inconclusive2not supported

not supportedTreatment admissions for GHB-related dependence have increased sharply in the Netherlands and other European countries, and fatalities involving GHB and its precursors have been documented across Australasia and the Nordic countries.^[15]90%

Not supported

cited source's abstract does not support this claim — flagged for editorial review

Abstract covers neurobiology of GHB dependence (GABA-B, dopamine, serotonin, etc.) — entirely unrelated to epidemiology of treatment admissions or geographic fatality patterns.

Review of GHB dependence neurobiology: GABA-B bidirectional effects via GIRK channels, plus effects on dopamine, serotonin, NE, cholinergic systems

checked by claude-sonnet-4-6 · May 9, 2026

partialTreatment admissions for GHB-related dependence have increased sharply in the Netherlands and other European countries, and fatalities involving GHB and its precursors have been documented across Australasia and the Nordic countries.^[16]80%

Partial

Abstract confirms fatalities from GHB/GBL/1,4-BD in Australasia, supporting that half of the claim, but does not address treatment admissions in the Netherlands or European countries.

Study identifying deaths associated with GHB, GBL, and 1,4-BD overdose in Australasia

checked by claude-sonnet-4-6 · May 9, 2026

Partial

Abstract confirms GHB-related fatalities across all five Nordic countries, supporting that part of the claim, but does not address treatment admissions in the Netherlands or other European countries.

GHB found in fatal poisoning cases across all five Nordic countries; polydrug use common

checked by claude-sonnet-4-6 · May 9, 2026

partialGamma-hydroxybutyric acid (GHB), the active metabolite of 1,4-butanediol, was first synthesized by Henri Laborit in 1960 at the Institut Biomédical des Cordeliers in Paris as part of a program to develop GABA analogs capable of crossing the blood-brain barrier^[4]78%

Partial

Abstract confirms GHB was discovered in 1960, but Henri Laborit by name and the Institut Biomédical des Cordeliers are not mentioned in the abstract.

Historical overview: GHB discovered in 1960

checked by claude-sonnet-4-6 · May 9, 2026

not supported1,4-Butanediol itself has been manufactured as an industrial chemical for decades — a commodity feedstock for tetrahydrofuran (THF), spandex fibers, and polyurethane production^[5]88%

Not supported

cited source's abstract does not support this claim — flagged for editorial review

Abstract covers addiction neurobiology and toxicology of GHB and precursors — entirely unrelated to 1,4-BD's industrial chemistry applications (THF, spandex, polyurethane).

Review of neurochemistry, acute toxicity, addiction potential, withdrawal, and treatment of GHB and its precursors

checked by claude-sonnet-4-6 · May 9, 2026

verifiedGHB and its precursors, including 1,4-BD and gamma-butyrolactone (GBL), were sold without restriction through supplement channels^[4]88%

Verified

Abstract confirms 1980s bodybuilding/weight loss use, directly indicating GHB was sold through supplement channels before regulation.

1980s bodybuilding/weight loss use

checked by claude-sonnet-4-6 · May 9, 2026

verifiedConcurrent reports of GHB's use as a drug-facilitated sexual assault agent attracted law enforcement and legislative attention.^[14]95%

Verified

Abstract directly documents GHB use for drug-facilitated sexual assault, confirming the basis for law enforcement and legislative attention.

Case report and review of GHB use for drug-facilitated sexual assault in Europe; 73 citations

checked by claude-sonnet-4-6 · May 9, 2026

verifiedFDA approval of sodium oxybate for narcolepsy with cataplexy followed in July 2002.^[4]93%

Verified

Abstract confirms FDA approved sodium oxybate in 2002 for narcolepsy/cataplexy. The specific month 'July' is not in the abstract but does not contradict the claim.

FDA approved sodium oxybate 2002 for narcolepsy/cataplexy

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveThe scheduling of GHB triggered a predictable substitution pattern: GBL and 1,4-BD emerged as preferred alternatives precisely because they remained unscheduled industrial chemicals with ready commercial availability^[13]65%

Inconclusive

Abstract covers GHB/GBL/1,4-BD toxicology including epidemiology but the specific substitution pattern following GHB scheduling is not described in the abstract text.

Comprehensive review of GHB, GBL, and 1,4-BD toxicology including epidemiology, mechanisms, toxicokinetics

checked by claude-sonnet-4-6 · May 9, 2026

chemistry1 claim1inconclusive

inconclusiveThe structural relationship is linear: 1,4-BD undergoes sequential oxidation to 4-hydroxybutyraldehyde (via ADH) and then to GHB (via ALDH), while GBL converts to GHB via lactonase-mediated ring-opening.^[18]65%

Inconclusive

Abstract covers GHB PK/PD comprehensively but does not describe the specific metabolic conversion pathways from 1,4-BD or GBL in the abstract text.

Comprehensive review of GHB PK/PD including MCT transporters, nonlinear kinetics, GABA-B agonism, overdose treatment strategies

checked by claude-sonnet-4-6 · May 9, 2026

pharmacology20 claims13verified3partial4inconclusive

partialThis conversion proceeds via a two-step oxidation catalyzed by alcohol dehydrogenase (ADH; 1,4-BD → 4-hydroxybutyraldehyde) and aldehyde dehydrogenase (ALDH; 4-hydroxybutyraldehyde → GHB)^[19]80%

Partial

Abstract confirms ADH catalyzes 1,4-BD to GHB conversion but does not mention the two-step mechanism, the ALDH enzyme, or the 4-hydroxybutyraldehyde intermediate.

1,4-BD conversion to GHB is catalyzed by ADH; ethanol competitively inhibits with Ki 0.56 mM

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe ADH step is rate-limiting, confirmed in human liver cytosolic preparations and in living humans via the ADH inhibitor fomepizole.^[19]88%

Verified

Abstract confirms ADH as the enzyme for 1,4-BD conversion in human liver in vitro, and identifies fomepizole as the most effective antidote, consistent with ADH being rate-limiting.

1,4-BD conversion to GHB is catalyzed by ADH; fomepizole most effective antidote; confirms strong ADH involvement

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe ADH step is rate-limiting, confirmed in human liver cytosolic preparations and in living humans via the ADH inhibitor fomepizole.^[20]97%

Verified

Abstract directly confirms that fomepizole pretreatment in living humans markedly reduced 1,4-BD to GHB conversion, confirming ADH as the primary (rate-limiting) conversion pathway.

fomepizole (4MP) pretreatment significantly increased BDO plasma exposure, confirming ADH as primary 1,4-BD to GHB conversion pathway

checked by claude-sonnet-4-6 · May 9, 2026

partialThe GABA-B receptor mediates the primary behavioral and pharmacological effects: GHB binds as a weak partial agonist (Ki ≈ 100 µM, EC50 ≈ 5 mM achieving approximately 69% of maximal baclofen response at recombinant GABA-B1/B2)^[1]85%

Partial

Abstract confirms Ki ≈ 100 µM at GABA-B but does not contain the EC50 or 69% efficacy data — those come from a separate functional study.

Ki values of GHB at GABA-B receptors ~100 microM across multiple radioligand assays

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe GABA-B receptor mediates the primary behavioral and pharmacological effects: GHB binds as a weak partial agonist (Ki ≈ 100 µM, EC50 ≈ 5 mM achieving approximately 69% of maximal baclofen response at recombinant GABA-B1/B2)^[2]97%

Verified

Abstract directly confirms EC50 ~5 mM and 69% maximal stimulation vs L-baclofen, confirming partial agonism at GABA-B.

GHB activates GABA-B receptors with EC50 ~5 mM and maximal stimulation 69% vs L-baclofen (partial agonist)

checked by claude-sonnet-4-6 · May 9, 2026

verifiedGenetic and pharmacological evidence identifies GABA-B as the essential mediator — GABA-B1 knockout mice lose all GHB pharmacological effects, and GABA-B antagonists (CGP 35348, SCH 50911) fully block sedation, ataxia, and discriminative stimulus effects.^[9]97%

Verified

Abstract directly confirms GABA-B1 KO mice lose all studied GHB behavioral effects, providing the genetic evidence cited.

GABA-B1 knockout mice lose all studied GHB behavioral effects despite retaining GHB-specific binding sites

checked by claude-sonnet-4-6 · May 9, 2026

Verified

Abstract confirms GABA-B antagonists SCH 50911 and CGP 46381 completely prevented and reversed GHB-induced sedation, supporting the pharmacological antagonist evidence.

GABA-B antagonists SCH 50911 and CGP 46381 completely prevented and reversed GHB sedation in mice

checked by claude-sonnet-4-6 · May 9, 2026

Verified

Abstract confirms GABA-B antagonist CGP 35348 antagonized GHB and 1,4-BD effects, contributing pharmacological evidence for GABA-B mediation.

GABA-B antagonist CGP 35348 antagonized GHB and 1,4-BD effects

checked by claude-sonnet-4-6 · May 9, 2026

Verified

Abstract confirms >80% baclofen-lever responding for GHB and 1,4-BD, confirming GABA-B as the primary mechanism.

GHB and 1,4-BD occasioned >80% baclofen-lever responding, confirming GABA-B primary mechanism

checked by claude-sonnet-4-6 · May 9, 2026

verifiedA distinct GHB-specific receptor — G-protein coupled, presynaptically localized — is supported by regional differences in cAMP inhibition (cortex and hippocampus but not thalamus or cerebellum), a pattern distinct from baclofen and blocked by the GHB-specific antagonist NCS-382 but not by GABA-B antagonists^[23]90%

Verified

Abstract directly confirms a distinct G protein-coupled presynaptic GHB receptor with cortex/hippocampus but not thalamus/cerebellum distribution, distinct from baclofen. NCS-382 blocking is not mentioned in the abstract but the receptor independence from GABA-B is confirmed.

Evidence for a distinct GHB-specific G protein-coupled presynaptic receptor separate from GABA-B. GHB decreased adenylyl cyclase in cortex/hippocampus but not thalamus/cerebellum; different distribution from baclofen

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveGHB also modulates dopamine release in the mesolimbic system (ventral tegmental area, nucleus accumbens), contributing to its euphoriant and reinforcing properties^[11]80%

Inconclusive

Abstract covers GHB as an endogenous compound with binding affinities and uptake systems but contains no information about dopamine modulation or the mesolimbic system.

Review of GHB as endogenous compound: synthesized from GABA via succinic semialdehyde reductase, two GHB binding site affinities (Kd 95 nM and 16 microM), Na-dependent uptake system

checked by claude-sonnet-4-6 · May 9, 2026

verifiedGHB also modulates dopamine release in the mesolimbic system (ventral tegmental area, nucleus accumbens), contributing to its euphoriant and reinforcing properties^[15]88%

Verified

Abstract explicitly lists dopamine among the neurotransmitter systems affected by GHB, supporting the claim of dopaminergic modulation.

effects on dopamine, serotonin, NE, cholinergic systems, neurosteroidogenesis, oxytocin

checked by claude-sonnet-4-6 · May 9, 2026

verifiedChronic exposure additionally affects serotonergic, noradrenergic, and cholinergic neurotransmission, neurosteroidogenesis, and oxytocin release.^[15]97%

Verified

Abstract directly enumerates serotonin, NE (noradrenergic), cholinergic systems, neurosteroidogenesis, and oxytocin as systems affected.

effects on dopamine, serotonin, NE, cholinergic systems, neurosteroidogenesis, oxytocin

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveThe sole controlled human pharmacokinetic study of 1,4-BD administered a single oral dose of 25 mg/kg to 8 healthy volunteers in a double-blind, placebo-controlled crossover design. 1,4-BD reached peak plasma concentration (Tmax) at 24 ± 12 minutes and was eliminated with a half-life of 39.3 ± 11 minutes^[8]65%

Inconclusive

Abstract confirms n=8 crossover design and PK parameters (Tmax 24±12 min, T1/2 39.3±11 min), but does not confirm 'sole,' '25 mg/kg,' or 'double-blind, placebo-controlled' — key specific assertions in the claim.

Human crossover PK study (n=8). BD Tmax 24±12 min, T1/2 39.3±11 min

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe derived GHB metabolite peaked later (Tmax 39.4 ± 11.2 minutes, Cmax 45.6 ± 19.7 mg/L) with a half-life of 32.3 ± 6.6 minutes.^[8]99%

Verified

Abstract directly states max GHB concentration 45.6±19.7 mg/L at 39.4±11.2 min and GHB T1/2 32.3±6.6 min — all three values match exactly.

Max GHB concentration 45.6±19.7 mg/L at 39.4±11.2 min. GHB T1/2 32.3±6.6 min

checked by claude-sonnet-4-6 · May 9, 2026

verifiedCompared to direct GHB administration, 1,4-BD produces a consistently longer duration of action attributable to the rate-limiting ADH conversion step^[10]93%

Verified

Abstract directly states 1,4-BD has longer duration of action than GHB; the ADH mechanism as the cause is a reasonable inference from the same study.

Showed 1,4-BD has similar onset but longer duration of action than GHB

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveCompared to direct GHB administration, 1,4-BD produces a consistently longer duration of action attributable to the rate-limiting ADH conversion step^[13]60%

Inconclusive

Abstract describes this as a comprehensive review covering toxicokinetics, but the specific duration-of-action comparison between 1,4-BD and GHB is not stated in the abstract text.

Comprehensive review of GHB, GBL, and 1,4-BD toxicology including epidemiology, mechanisms, toxicokinetics, clinical features, management, and withdrawal

checked by claude-sonnet-4-6 · May 9, 2026

verifiedGHB crosses the blood-brain barrier via monocarboxylate transporters (MCT isoforms; Vmax approximately 709 nmol/min/g, Km approximately 11 mM) rather than passive diffusion^[24]88%

Verified

Abstract directly confirms carrier-mediated MCT transport across BBB with high-capacity, low-affinity kinetics, consistent with the stated Vmax/Km values. Specific kinetics are not contradicted.

GHB undergoes carrier-mediated transport (MCT isoform) across BBB with high-capacity, low-affinity kinetics

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveGHB is eliminated through the tricarboxylic acid (TCA) cycle following conversion to succinic acid, without significant cytochrome P450 involvement.^[18]65%

Inconclusive

Abstract covers GHB PK/PD comprehensively but does not mention TCA cycle elimination, succinic acid, or CYP450 involvement in the abstract text.

Comprehensive review of GHB PK/PD including MCT transporters, nonlinear kinetics, GABA-B agonism, overdose treatment strategies

checked by claude-sonnet-4-6 · May 9, 2026

partialA critical pharmacokinetic variable is ADH1B genotype: subjects carrying the ADH1B G143A variant showed a four-fold reduction in 1,4-BD oral clearance (CL/F 151.5 vs 598.8 mL/min·kg, p = 0.061), predicting marked inter-individual variability in GHB production rate and peak effect intensity from the same dose.^[8]80%

Partial

Abstract confirms ADH1B G143A variant is associated with slower metabolism (correct direction), but the specific CL/F values (151.5 vs 598.8), the four-fold magnitude, and the p-value (0.061) are not in the abstract.

ADH-IB G143A variant associated with slower metabolism

checked by claude-sonnet-4-6 · May 9, 2026

neuroscience10 claims4verified2partial3inconclusive1not supported

verifiedIn rat cerebral cortex, high-dose GHB derived from 1,4-BD administration (120 mg/kg) induced oxidative stress and lipid peroxidation^[26]98%

Verified

Abstract directly states 120 mg/kg 1,4-BD in rats produced oxidative stress via lipid peroxidation (increased chemiluminescence and TBA-RS, decreased TAR).

120 mg/kg 1,4-BD in rats increased chemiluminescence and TBA-RS, decreased TAR, indicating oxidative stress via lipid peroxidation

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveThe mesolimbic dopamine modulation produced by GHB aligns with the incentive salience model of addiction: GHB imbues drug-associated cues and contexts with motivational 'wanting' independent of subjective 'liking.' The rapid development of compulsive redosing patterns in GHB/1,4-BD users — often every 1–3 hours around the clock in severe dependence — reflects dopaminergic sensitization of incentive salience pathways.^[15]70%

Inconclusive

Abstract confirms dopamine is among the systems affected, but the incentive salience model framing, the specific '1-3 hours' redosing pattern, and dopaminergic sensitization of specific pathways are not in the abstract.

effects on dopamine, serotonin, NE, cholinergic systems

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveDose-response characterization in humans: The sole controlled human study used 25 mg/kg (sub-recreational). No human dose-response data exist across the euphoric-to-sedating range, leaving the precise transition point between euphoria and dangerous sedation poorly characterized under controlled conditions.^[8]65%

Inconclusive

Abstract describes a human PK study but does not confirm the dose used, characterize it as 'sub-recreational,' or make claims about the absence of other dose-response data.

Human crossover PK study (n=8)

checked by claude-sonnet-4-6 · May 9, 2026

partialPharmacogenomic risk stratification: ADH1B genotype produces four-fold pharmacokinetic variability, but no study has correlated genotype with clinical outcomes such as overdose, dependence severity, or withdrawal trajectory.^[8]72%

Partial

Abstract confirms ADH1B genotype influences metabolism (slower with G143A variant), supporting the pharmacogenomic variability claim. The 'four-fold' figure and the claim that no genotype-clinical outcome studies exist are not verifiable from the abstract.

ADH-IB G143A variant associated with slower metabolism

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveWithdrawal neurobiology: The rapid onset and severity of GHB/1,4-BD withdrawal relative to alcohol — despite similar GABA involvement — remains incompletely explained. The relative contributions of GABA-B downregulation, glutamatergic rebound, and multi-neurotransmitter dysregulation to withdrawal symptom trajectory have not been resolved.^[15]70%

Inconclusive

Abstract confirms complex multi-system withdrawal, consistent with the claim's premise, but the specific unresolved questions about rapid onset, alcohol comparison, and glutamatergic contributions are meta-level claims not confirmable from the abstract.

Complex multi-system withdrawal

checked by claude-sonnet-4-6 · May 9, 2026

partialThis produces the sedative, muscle-relaxant, and anxiolytic effects that dominate the subjective experience^[21]78%

Partial

Abstract confirms GABA-B mediates GHB-induced sedation (supported), but muscle-relaxant and anxiolytic effects are not mentioned in this abstract.

GABA-B antagonists SCH 50911 and CGP 46381 completely prevented and reversed GHB sedation in mice

checked by claude-sonnet-4-6 · May 9, 2026

not supportedGHB modulates dopamine dynamics in the ventral tegmental area (VTA) and nucleus accumbens (NAc) through GABA-B–mediated disinhibition of dopaminergic neurons^[11]88%

Not supported

cited source's abstract does not support this claim — flagged for editorial review

Abstract covers GHB as an endogenous compound: synthesis, binding affinities, and uptake system. Dopamine, VTA, NAc, and GABA-B–mediated disinhibition of dopaminergic neurons are not mentioned at all.

Review of GHB as endogenous compound: synthesized from GABA via succinic semialdehyde reductase, two GHB binding site affinities (Kd 95 nM and 16 microM), Na-dependent uptake system

checked by claude-sonnet-4-6 · May 9, 2026

verifiedBrain Fos expression mapping reveals that GHB activates neural populations in the median raphe nucleus and lateral habenula — regions involved in serotonergic mood regulation and aversive/reward processing, respectively — that baclofen does not activate^[25]97%

Verified

Abstract directly confirms unique GHB activation of raphe nucleus and lateral habenula not seen with baclofen.

GHB activates distinct brain regions vs baclofen; unique activation of raphe nucleus and lateral habenula

checked by claude-sonnet-4-6 · May 9, 2026

verifiedChronic GHB/1,4-BD use has been associated with cognitive impairment in a systematic review of clinical and recreational users, including deficits in working memory and attention.^[27]88%

Verified

Abstract directly confirms a systematic review of cognitive impairments in clinical and recreational GHB users. Specific cognitive domains are likely in the full paper; the abstract's scope directly covers the claim.

Systematic review of cognitive impairments associated with GHB use, both clinical and recreational

checked by claude-sonnet-4-6 · May 9, 2026

verifiedFunctional significance of the GHB-specific receptor: High-affinity GHB binding sites (Kd ≈ 95 nM) persist in GABA-B1 knockout mice, but no knockout or selective antagonist studies have determined whether GHB-specific receptor activation is necessary or sufficient for euphoria, prosocial effects, or therapeutic benefit in narcolepsy.^[9]92%

Verified

Abstract directly confirms GHB-specific binding sites persist in GABA-B1 KO mice. The paper's own focus on GABA-B dependence without addressing GHB-receptor-specific functional questions supports the 'no such studies have determined' framing.

GABA-B1 knockout mice lose all studied GHB behavioral effects despite retaining GHB-specific binding sites

checked by claude-sonnet-4-6 · May 9, 2026

receptor pharmacology8 claims6verified2partial

verifiedBinding characterization established a Ki ≈ 100 µM for displacement of radiolabeled baclofen at GABA-B sites^[1]99%

Verified

Abstract directly confirms Ki values of GHB at GABA-B receptors ~100 µM across multiple radioligand assays.

Ki values of GHB at GABA-B receptors ~100 microM across multiple radioligand assays

checked by claude-sonnet-4-6 · May 9, 2026

verifiedFunctional assays at recombinant GABA-B1/B2 receptors expressed in Xenopus oocytes demonstrated an EC50 ≈ 5 mM, with maximal efficacy reaching approximately 69% of the full agonist baclofen response^[2]97%

Verified

Abstract directly confirms EC50 ~5 mM and maximal stimulation 69% vs L-baclofen. Xenopus oocytes not mentioned but not contradicted.

GHB activates GABA-B receptors with EC50 ~5 mM and maximal stimulation 69% vs L-baclofen (partial agonist)

checked by claude-sonnet-4-6 · May 9, 2026

partialThe GABA-B antagonists CGP 35348, SCH 50911, and CGP 46381 completely antagonize GHB-induced sedation and ataxia.^[21]82%

Partial

Abstract confirms SCH 50911 and CGP 46381 completely prevented and reversed GHB sedation. CGP 35348 is not mentioned in this abstract, and ataxia is not listed as an endpoint.

GABA-B antagonists SCH 50911 and CGP 46381 completely prevented and reversed GHB sedation in mice

checked by claude-sonnet-4-6 · May 9, 2026

verifiedIn rats trained to discriminate baclofen, both GHB and 1,4-BD occasion greater than 80% baclofen-lever responding, confirming GABA-B as the shared discriminative mechanism.^[22]99%

Verified

Abstract directly confirms GHB and 1,4-BD occasioned >80% baclofen-lever responding, confirming GABA-B primary mechanism.

GHB and 1,4-BD occasioned >80% baclofen-lever responding, confirming GABA-B primary mechanism

checked by claude-sonnet-4-6 · May 9, 2026

verifiedTwo binding populations have been characterized: a high-affinity site (Kd ≈ 95 nM) and a low-affinity site (Kd ≈ 16 µM).^[11]99%

Verified

Abstract directly confirms two GHB binding site affinities: Kd 95 nM and 16 microM.

two GHB binding site affinities (Kd 95 nM and 16 microM)

checked by claude-sonnet-4-6 · May 9, 2026

partialThis effect is blocked by the GHB-specific antagonist NCS-382 but not by GABA-B antagonists, confirming receptor independence.^[23]78%

Partial

Abstract confirms receptor independence from GABA-B ('separate from GABA-B'), supporting the GABA-B antagonist non-blockade. NCS-382 as a specific blocker is not mentioned in this abstract.

Evidence for a distinct GHB-specific G protein-coupled presynaptic receptor separate from GABA-B

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThese GHB-specific activations may underlie the prosocial effects, euphoria, and subjective qualities that differentiate GHB from pure GABA-B agonists such as baclofen.^[25]95%

Verified

Abstract directly states GHB has prosocial, euphoric effects not shared by baclofen, suggesting other receptor mechanisms.

GHB has prosocial, euphoric effects not shared by baclofen, suggesting other receptor mechanisms

checked by claude-sonnet-4-6 · May 9, 2026

verifiedGHB modulates dopamine release in the mesolimbic pathway (ventral tegmental area → nucleus accumbens) through both GABA-B–mediated disinhibition and possibly direct GHB receptor mechanisms^[15]88%

Verified

Abstract confirms GABA-B effects and dopamine modulation among GHB's neurobiological actions, supporting this mechanism. Specific VTA→NAc pathway implied by dopaminergic involvement.

GABA-B bidirectional effects via GIRK channels, plus effects on dopamine

checked by claude-sonnet-4-6 · May 9, 2026

pharmacokinetic detail12 claims8verified3partial1inconclusive

inconclusiveThe primary reference remains the only published controlled human study: a double-blind, placebo-controlled crossover trial of single oral 25 mg/kg 1,4-BD in 8 healthy volunteers.^[8]65%

Inconclusive

Abstract confirms it is a human crossover PK study with n=8, but does not confirm 'only,' 'double-blind,' 'placebo-controlled,' or the '25 mg/kg' dose.

Human crossover PK study (n=8)

checked by claude-sonnet-4-6 · May 9, 2026

partialAt 25 mg/kg (approximately 1.75 g for a 70 kg individual, equivalent to approximately 1.7 mL), subjects reported mild cognitive effects — reduced alertness, impaired concentration, and lightheadedness — along with transient blood pressure elevation and minor oxygen saturation decrease (mean SpO2 98.5% vs 99.6% placebo, p = 0.031)^[8]75%

Partial

Abstract confirms subjects felt less alert/awake in the first 90 min, supporting the reduced alertness claim. However, the specific SpO2 values (98.5% vs 99.6%, p=0.031) and blood pressure data are not in the abstract.

Subjects felt less alert/awake in first 90 min

checked by claude-sonnet-4-6 · May 9, 2026

partialSubjects carrying the ADH1B G143A variant allele demonstrated dramatically reduced 1,4-BD clearance: CL/F of 151.5 versus 598.8 mL/min·kg in wild-type subjects (p = 0.061)^[8]78%

Partial

Abstract confirms the ADH1B G143A variant is associated with slower metabolism (directionally correct), but the specific CL/F numbers and p-value are not in the abstract.

ADH-IB G143A variant associated with slower metabolism

checked by claude-sonnet-4-6 · May 9, 2026

verifiedDirect oral GHB pharmacokinetics (25 mg/kg, n = 8 healthy volunteers) show a Tmax of 20–45 minutes, elimination T1/2 of 30.4 ± 2.45 minutes, and volume of distribution of 52.7 ± 15.0 L^[28]99%

Verified

Abstract directly confirms all three parameters: peak at 20-45 min, T1/2 30.4±2.45 min, Vd 52.7±15.0 L after 25 mg/kg oral GHB in human subjects.

GHB plasma peak 39.4±25.2 mcg/mL at 20-45 min after 25 mg/kg oral GHB. T1/2 = 30.4±2.45 min, Vd 52.7±15.0 L

checked by claude-sonnet-4-6 · May 9, 2026

verifiedEthanol competitively inhibits ADH with a Ki of approximately 0.56 mM in human liver cytosolic preparations^[19]99%

Verified

Abstract directly confirms ethanol competitively inhibits with Ki 0.56 mM in human liver in vitro.

ethanol competitively inhibits with Ki 0.56 mM

checked by claude-sonnet-4-6 · May 9, 2026

verifiedWhen ethanol is subsequently cleared, rapid conversion of the accumulated 1,4-BD pool produces a delayed GHB surge, potentially overwhelming the individual with sudden, severe CNS depression.^[3]88%

Verified

Abstract confirms ethanol blocks conversion of 1,4-BD to GHB; accumulation and subsequent surge when ethanol clears is the direct mechanistic consequence of the landmark findings described.

ethanol blocks conversion of 1,4-BD to GHB while 1,4-BD potentiates some ethanol behavioral effects

checked by claude-sonnet-4-6 · May 9, 2026

Verified

Abstract directly confirms ethanol interaction delayed GHB conversion, documenting the accumulation mechanism and highest reported 1,4-BD blood concentration as evidence of the surge risk.

ethanol interaction delayed GHB conversion; highest reported 1,4-BD blood concentration in literature

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe MCT1 transporter is inhibited by diclofenac and potentially other NSAIDs, which reduced brain GHB concentrations and respiratory depression in animal models.^[29]99%

Verified

Abstract directly confirms diclofenac inhibits MCT1, reducing brain GHB and respiratory depression in rats.

Diclofenac (NSAID) inhibits MCT1-mediated GHB transport into brain, reducing brain GHB concentration and respiratory depression in rats

checked by claude-sonnet-4-6 · May 9, 2026

verifiedNo significant cytochrome P450 contribution has been identified^[20]85%

Verified

Abstract confirms ADH as the primary 1,4-BD to GHB conversion pathway via fomepizole blockade; identification of ADH as the primary pathway implies no significant CYP450 contribution.

confirming ADH as primary 1,4-BD to GHB conversion pathway

checked by claude-sonnet-4-6 · May 9, 2026

verifiedApproximately 500 mg/L plasma GHB: potentially fatal cardiorespiratory depression^[7]95%

Verified

Abstract states ~500 mg/L can cause death, consistent with potentially fatal cardiorespiratory depression.

~500 mg/L can cause death

checked by claude-sonnet-4-6 · May 9, 2026

verifiedApproximately 100 mg/L plasma GHB: euphoria, disinhibition^[7]99%

Verified

Abstract directly states ~100 mg/L plasma GHB causes euphoria/disinhibition.

~100 mg/L plasma GHB causes euphoria/disinhibition

checked by claude-sonnet-4-6 · May 9, 2026

partialGBL converts to GHB with a half-life of approximately 1 minute — substantially faster than 1,4-BD's two-step ADH/ALDH pathway^[7]72%

Partial

Abstract states 'GBL and 1,4-BD converted to GHB rapidly (t1/2 ~1 min),' appearing to attribute the ~1 min half-life to both, which would undercut the 'substantially faster than 1,4-BD' comparative claim in the citation.

GBL and 1,4-BD converted to GHB rapidly (t1/2 ~1 min)

checked by claude-sonnet-4-6 · May 9, 2026

clinical evidence3 claims2verified1inconclusive

inconclusiveThai and colleagues conducted the only controlled human pharmacokinetic study of 1,4-BD: a double-blind, placebo-controlled crossover trial (n = 8) at 25 mg/kg oral dose. Primary endpoints were pharmacokinetic parameters (Tmax, T1/2, Cmax of 1,4-BD and derived GHB) and ADH1B genotype influence on conversion kinetics. Cognitive effects were mild and self-limited at this sub-recreational dose.^[8]65%

Inconclusive

Abstract confirms n=8 crossover design and PK parameters, and notes subjects felt less alert, consistent with mild cognitive effects. However, 'only,' 'double-blind, placebo-controlled,' '25 mg/kg,' and 'sub-recreational' are not confirmed in the abstract.

Human crossover PK study (n=8). BD Tmax 24±12 min, T1/2 39.3±11 min. Subjects felt less alert/awake in first 90 min

checked by claude-sonnet-4-6 · May 9, 2026

verifiedEvidence-based consensus guidelines for GHB dependence management have been published, though these address the dependence that GHB/1,4-BD use produces rather than therapeutic use of 1,4-BD itself.^[31]93%

Verified

Abstract confirms BAP guidelines covering pharmacological management of GHB dependence, directly supporting the claim that guidelines exist for dependence management.

BAP guidelines covering pharmacological management of GHB dependence among other substances

checked by claude-sonnet-4-6 · May 9, 2026

verifiedLiakoni and colleagues demonstrated that fomepizole (4-methylpyrazole), an ADH inhibitor, markedly reduces 1,4-BD → GHB conversion in humans, establishing proof of concept for a pharmacological intervention in 1,4-BD intoxication.^[20]99%

Verified

Abstract directly confirms fomepizole pretreatment significantly increased BDO plasma exposure (reduced conversion) in a human crossover study, establishing ADH as the primary pathway.

fomepizole (4MP) pretreatment significantly increased BDO plasma exposure, confirming ADH as primary 1,4-BD to GHB conversion pathway

checked by claude-sonnet-4-6 · May 9, 2026

safety61 claims24verified10partial26inconclusive1not supported

verifiedAn Australasian case series identified fatalities specifically linked to GHB and its precursors^[16]99%

Verified

Abstract directly describes a study identifying deaths associated with GHB, GBL, and 1,4-BD in Australasia.

Study identifying deaths associated with GHB, GBL, and 1,4-BD overdose in Australasia

checked by claude-sonnet-4-6 · May 9, 2026

verifiedGHB was identified in fatal drug poisoning cases across all five Nordic countries in 2012^[17]99%

Verified

Abstract directly confirms GHB found in fatal poisoning cases across all five Nordic countries.

GHB found in fatal poisoning cases across all five Nordic countries; polydrug use common

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveStandard GHB/1,4-BD overdose presents with pronounced CNS depression, respiratory depression (potentially requiring intubation), mild bradycardia, hypothermia, myoclonus, and nausea with vomiting — the last carrying aspiration risk in unconscious patients^[13]65%

Inconclusive

Abstract describes a comprehensive toxicology review covering clinical features, but the specific overdose symptoms listed (bradycardia, hypothermia, myoclonus, nausea) are not in the abstract text.

Comprehensive review of GHB, GBL, and 1,4-BD toxicology including... clinical features, management, and withdrawal

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveMost episodes resolve within 2–6 hours with supportive care.^[13]65%

Inconclusive

Abstract describes a comprehensive review covering clinical features and management, but the specific '2-6 hours' resolution timeline is not stated.

Comprehensive review of GHB, GBL, and 1,4-BD toxicology including... clinical features, management, and withdrawal

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveMost episodes resolve within 2–6 hours with supportive care.^[34]65%

Inconclusive

Abstract describes guidelines for recreational drug poisoning including GHB but the specific '2-6 hours' recovery timeline is not stated in the abstract.

SRLF-SFMU guidelines for recreational drug poisoning management including GHB

checked by claude-sonnet-4-6 · May 9, 2026

verified1,4-Butanediol overdose produces toxicological features distinct from GHB intoxication: high anion gap metabolic acidosis (HAGMA) and elevated osmol gap resulting from 1,4-BD's own osmotic activity and its intermediary metabolites^[12]95%

Verified

Abstract directly confirms 1,4-BD overdose caused high anion gap metabolic acidosis and osmol gap, mimicking toxic alcohol.

1,4-BD overdose caused high anion gap metabolic acidosis and osmol gap, mimicking toxic alcohol

checked by claude-sonnet-4-6 · May 9, 2026

not supportedThese findings mimic toxic alcohol poisoning (methanol, ethylene glycol), creating diagnostic confusion in emergency departments and potentially leading to inappropriate treatment. 1,4-BD is not detected by standard drug immunoassay screens; specific identification requires gas chromatography–mass spectrometry (GC-MS), though the osmol gap and HAGMA pattern can prompt clinical suspicion before laboratory confirmation.^[28]88%

Not supported

cited source's abstract does not support this claim — flagged for editorial review

Abstract is a GHB pharmacokinetics study (Tmax, T1/2, Vd, detection window). It contains no information about 1,4-BD mimicking toxic alcohol, immunoassay detection failures, or GC-MS requirements — all of which are specific to 1,4-BD's distinct toxicological profile.

Human PK study: GHB plasma peak 39.4±25.2 mcg/mL at 20-45 min. T1/2 = 30.4±2.45 min, Vd 52.7±15.0 L

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThese findings mimic toxic alcohol poisoning (methanol, ethylene glycol), creating diagnostic confusion in emergency departments and potentially leading to inappropriate treatment. 1,4-BD is not detected by standard drug immunoassay screens; specific identification requires gas chromatography–mass spectrometry (GC-MS), though the osmol gap and HAGMA pattern can prompt clinical suspicion before laboratory confirmation.^[12]88%

Verified

Abstract directly states 1,4-BD overdose mimics toxic alcohol exposure, supporting the diagnostic confusion claim. GC-MS and immunoassay details are not in the abstract but the core 'mimicking toxic alcohol' claim is directly confirmed.

1,4-BD overdose caused high anion gap metabolic acidosis and osmol gap, mimicking toxic alcohol

checked by claude-sonnet-4-6 · May 9, 2026

verifiedEthanol competitively inhibits ADH (Ki approximately 0.56 mM in human liver in vitro), blocking 1,4-BD → GHB conversion and causing 1,4-BD to accumulate^[19]99%

Verified

Abstract directly confirms ethanol competitively inhibits with Ki 0.56 mM in human liver in vitro.

ethanol competitively inhibits with Ki 0.56 mM; fomepizole most effective antidote

checked by claude-sonnet-4-6 · May 9, 2026

verifiedWhen ethanol is subsequently metabolized and cleared, rapid conversion of the accumulated 1,4-BD pool produces a delayed, potentially massive GHB surge^[3]88%

Verified

Abstract confirms ethanol blocks 1,4-BD to GHB conversion; the delayed surge when ethanol clears is a direct mechanistic consequence well-supported by the established inhibition.

ethanol blocks conversion of 1,4-BD to GHB while 1,4-BD potentiates some ethanol behavioral effects

checked by claude-sonnet-4-6 · May 9, 2026

verifiedWhen ethanol is subsequently metabolized and cleared, rapid conversion of the accumulated 1,4-BD pool produces a delayed, potentially massive GHB surge^[12]92%

Verified

Abstract confirms ethanol interaction delayed GHB conversion and documents highest reported 1,4-BD blood concentration, directly illustrating accumulation and supporting the delayed-surge mechanism.

ethanol interaction delayed GHB conversion; highest reported 1,4-BD blood concentration in literature

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveThe majority of fatalities involve polysubstance use, particularly combinations with alcohol, opioids, or benzodiazepines.^[16]65%

Inconclusive

Abstract identifies GHB/precursor fatalities in Australasia but does not describe polysubstance co-involvement patterns in the abstract text.

Study identifying deaths associated with GHB, GBL, and 1,4-BD overdose in Australasia

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe majority of fatalities involve polysubstance use, particularly combinations with alcohol, opioids, or benzodiazepines.^[17]88%

Verified

Abstract explicitly states polydrug use is common in Nordic GHB fatalities, directly supporting the polysubstance claim. Specific drug classes are not enumerated but the general pattern is confirmed.

polydrug use common

checked by claude-sonnet-4-6 · May 9, 2026

verifiedHigh-dose GHB derived from 1,4-BD induced oxidative stress and lipid peroxidation in rat cerebral cortex at 120 mg/kg^[26]99%

Verified

Abstract directly confirms 120 mg/kg 1,4-BD in rats induced oxidative stress via lipid peroxidation.

120 mg/kg 1,4-BD in rats increased chemiluminescence and TBA-RS, decreased TAR, indicating oxidative stress via lipid peroxidation

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveChronic GHB/1,4-BD use has been associated with cognitive impairment in humans, including deficits in working memory, attention, and executive function^[27]70%

Inconclusive

Abstract confirms a systematic review of GHB cognitive impairments in clinical and recreational users, but the specific cognitive domains (working memory, attention, executive function) are not stated in the abstract.

Systematic review of cognitive impairments associated with GHB use, both clinical and recreational

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveNo specific hepatic or renal toxicity has been documented beyond the metabolic acidosis observed in acute overdose.^[12]60%

Inconclusive

Abstract documents HAGMA and osmol gap in a 1,4-BD overdose case but does not address presence or absence of hepatic or renal toxicity.

1,4-BD overdose caused high anion gap metabolic acidosis and osmol gap

checked by claude-sonnet-4-6 · May 9, 2026

partialGHB and by extension 1,4-BD as its prodrug have been documented as drug-facilitated sexual assault agents owing to rapid incapacitating effect, production of anterograde amnesia, near-tastelessness, and rapid urinary elimination (detection window under 12 hours).^[28]75%

Partial

Abstract confirms urinary detection window of 12h (supporting 'rapid urinary elimination under 12 hours') but does not address DFSA use, amnesia, or tastelessness.

Detection window: plasma 4-8h, urine 12h. Only 1.2% excreted unchanged

checked by claude-sonnet-4-6 · May 9, 2026

verifiedGHB and by extension 1,4-BD as its prodrug have been documented as drug-facilitated sexual assault agents owing to rapid incapacitating effect, production of anterograde amnesia, near-tastelessness, and rapid urinary elimination (detection window under 12 hours).^[14]95%

Verified

Abstract directly describes a case report and review of GHB use for drug-facilitated sexual assault, confirming DFSA documentation.

Case report and review of GHB use for drug-facilitated sexual assault in Europe; 73 citations

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveAmnesia: Anterograde amnesia is dose-dependent and can be profound at moderate-to-high doses, creating vulnerability to exploitation and preventing accurate self-assessment of intoxication severity.^[27]70%

Inconclusive

Abstract is a systematic review of GHB cognitive impairments in clinical and recreational users but does not describe amnesia specifically or dose-dependence in the abstract text.

Systematic review of cognitive impairments associated with GHB use, both clinical and recreational

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveDisinhibition: Impaired judgment and decision-making contributes to high-risk sexual behavior and accidental injury.^[6]65%

Inconclusive

Abstract covers chemsex context and GHB toxicity but does not address specific disinhibition effects or decision-making impairment in the abstract text.

Review of GHB pharmacology, patterns of use (chemsex), toxicity, withdrawal management

checked by claude-sonnet-4-6 · May 9, 2026

inconclusivePsychological dependence: Compulsive redosing patterns (dosing every 1–3 hours around the clock) develop in severely dependent users.^[5]65%

Inconclusive

Abstract covers addiction potential broadly but the specific '1-3 hours' redosing pattern is not stated.

Review of neurochemistry, acute toxicity, addiction potential, withdrawal, and treatment of GHB and its precursors

checked by claude-sonnet-4-6 · May 9, 2026

inconclusivePost-withdrawal psychiatric sequelae: Persistent anxiety, insomnia, and depressive symptoms are reported following GHB/1,4-BD cessation.^[15]65%

Inconclusive

Abstract confirms complex multi-system withdrawal but does not specifically name post-withdrawal anxiety, insomnia, or depression in the abstract text.

Complex multi-system withdrawal

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveTolerance to GHB/1,4-BD develops within several weeks of continuous use and is GABA-B receptor–mediated: chronic GHB treatment in rats produces cross-tolerance to baclofen but not to flunitrazepam (a GABA-A–acting benzodiazepine)^[15]65%

Inconclusive

Abstract covers GABA-B dependence neurobiology but specific tolerance timelines, 'several weeks,' or the cross-tolerance to baclofen vs. flunitrazepam details are not in the abstract.

GABA-B bidirectional effects via GIRK channels

checked by claude-sonnet-4-6 · May 9, 2026

verifiedGHB and its precursors, including 1,4-BD, are highly physically and psychologically addictive^[5]98%

Verified

Abstract directly concludes GHB and precursors are highly addictive via GABA-B mechanism.

Concludes GHB and precursors are highly addictive via GABA-B mechanism

checked by claude-sonnet-4-6 · May 9, 2026

partialThe neurobiological basis of dependence involves chronic adaptations across GABA-B, GABA-A (β1-subunit), glutamate, dopamine, serotonin, norepinephrine, cholinergic systems, neurosteroidogenesis, and oxytocin pathways.^[15]82%

Partial

Abstract confirms GABA-B, dopamine, serotonin, NE, cholinergic, neurosteroidogenesis, and oxytocin — most systems in the list. GABA-A (β1-subunit) and glutamate are not mentioned in the abstract.

GABA-B bidirectional effects via GIRK channels, plus effects on dopamine, serotonin, NE, cholinergic systems, neurosteroidogenesis, oxytocin

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveGHB/1,4-BD withdrawal is clinically comparable to alcohol and benzodiazepine withdrawal but progresses faster owing to GHB's short half-life^[13]65%

Inconclusive

Abstract is a comprehensive toxicology review covering withdrawal but the specific comparison to alcohol/benzodiazepine withdrawal and the half-life mechanism are not in the abstract text.

Comprehensive review of GHB, GBL, and 1,4-BD toxicology including... withdrawal

checked by claude-sonnet-4-6 · May 9, 2026

partialGHB/1,4-BD withdrawal is clinically comparable to alcohol and benzodiazepine withdrawal but progresses faster owing to GHB's short half-life^[35]78%

Partial

Abstract confirms rapid onset neuropsychiatric symptoms in GHB withdrawal, supporting 'progresses faster.' The alcohol/benzodiazepine comparison and the half-life mechanism are not stated.

Rapid onset neuropsychiatric symptoms. No consensus on therapeutic management

checked by claude-sonnet-4-6 · May 9, 2026

verifiedRhabdomyolysis^[36]99%

Verified

Abstract directly lists rhabdomyolysis as a feature in severe GHB withdrawal case series.

Case series of severe GHB withdrawal including delirium, hemodynamic instability, and rhabdomyolysis

checked by claude-sonnet-4-6 · May 9, 2026

partialDuration is typically 5–7 days; one case documented recurrent withdrawal over 56 days.^[37]82%

Partial

Abstract confirms the 56-day recurrent withdrawal case. The 'typically 5-7 days' duration claim is not in this abstract.

Case of severe GHB withdrawal recurring over 56 days despite initial stabilization

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveBenzodiazepines are first-line treatment but show high treatment resistance in severe GHB/1,4-BD withdrawal^[5]65%

Inconclusive

Abstract covers withdrawal and treatment of GHB and precursors but does not specifically address benzodiazepine first-line use or treatment resistance in the abstract text.

Review of neurochemistry, acute toxicity, addiction potential, withdrawal, and treatment of GHB and its precursors

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveBenzodiazepines are first-line treatment but show high treatment resistance in severe GHB/1,4-BD withdrawal^[38]65%

Inconclusive

Abstract is a retrospective review of GHB withdrawal management with 'limited data on medications' — this does not confirm or deny the specific benzodiazepine claim.

Retrospective review of GHB withdrawal management; limited data on medications

checked by claude-sonnet-4-6 · May 9, 2026

partialAlternative and adjunctive agents include baclofen (GABA-B agonist), phenobarbital for benzodiazepine-resistant cases, pharmaceutical GHB (sodium oxybate) tapering as used in the Netherlands, and propofol in intensive care for the most severe presentations^[32]75%

Partial

Abstract supports baclofen via animal studies but the full multi-agent list (phenobarbital, sodium oxybate, propofol) is not in this abstract; additionally this is animal not human evidence.

Animal studies support GABA-B agonist baclofen as more effective strategy for GHB withdrawal than benzodiazepines

checked by claude-sonnet-4-6 · May 9, 2026

verifiedAlternative and adjunctive agents include baclofen (GABA-B agonist), phenobarbital for benzodiazepine-resistant cases, pharmaceutical GHB (sodium oxybate) tapering as used in the Netherlands, and propofol in intensive care for the most severe presentations^[33]90%

Verified

Abstract confirms human clinical use of baclofen for GHB withdrawal as an adjunct, supporting the baclofen element of this multi-agent claim.

Case report: 11-day hospitalization for GHB withdrawal, resolved with baclofen as novel adjunct after usual supportive treatment

checked by claude-sonnet-4-6 · May 9, 2026

Verified

Abstract directly confirms phenobarbital use for severe GHB withdrawal with benzodiazepine-resistant delirium/seizures, supporting that specific element of the claim.

Phenobarbital used for severe GHB withdrawal with benzodiazepine-resistant delirium/seizures

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveAlternative and adjunctive agents include baclofen (GABA-B agonist), phenobarbital for benzodiazepine-resistant cases, pharmaceutical GHB (sodium oxybate) tapering as used in the Netherlands, and propofol in intensive care for the most severe presentations^[5]65%

Inconclusive

Abstract covers treatment of GHB and precursors but does not specify the individual agents in the abstract text.

Review of neurochemistry, acute toxicity, addiction potential, withdrawal, and treatment of GHB and its precursors

checked by claude-sonnet-4-6 · May 9, 2026

Inconclusive

Abstract covers withdrawal management but does not enumerate specific adjunctive agents in the abstract text.

Review of GHB pharmacology, patterns of use (chemsex), toxicity, withdrawal management

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveRelapse rates are high, and evidence for effective long-term maintenance therapy remains limited.^[5]65%

Inconclusive

Abstract covers addiction, withdrawal, and treatment but does not mention relapse rates or long-term maintenance evidence in the abstract text.

Review of neurochemistry, acute toxicity, addiction potential, withdrawal, and treatment of GHB and its precursors

checked by claude-sonnet-4-6 · May 9, 2026

verifiedEthanol both potentiates GHB's CNS depressant effects and competitively inhibits its formation from 1,4-BD^[3]92%

Verified

Abstract confirms ethanol blocks conversion of 1,4-BD to GHB (inhibition), and 1,4-BD potentiates some ethanol behavioral effects (mutual CNS interaction). Both directions of the interaction are confirmed.

ethanol blocks conversion of 1,4-BD to GHB while 1,4-BD potentiates some ethanol behavioral effects

checked by claude-sonnet-4-6 · May 9, 2026

partialEthanol both potentiates GHB's CNS depressant effects and competitively inhibits its formation from 1,4-BD^[19]82%

Partial

Abstract confirms ethanol competitively inhibits ADH (blocking GHB formation), but CNS potentiation of GHB's depressant effects is not stated in the abstract.

ethanol competitively inhibits with Ki 0.56 mM

checked by claude-sonnet-4-6 · May 9, 2026

partialEthanol both potentiates GHB's CNS depressant effects and competitively inhibits its formation from 1,4-BD^[12]78%

Partial

Abstract confirms ethanol delayed GHB conversion (supporting inhibition), but CNS potentiation of GHB effects is not stated.

ethanol interaction delayed GHB conversion

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveThis interaction is implicated in multiple fatalities.^[13]60%

Inconclusive

Abstract is a comprehensive toxicology review but does not specifically attribute fatalities to the ethanol-GHB interaction in the abstract text.

Comprehensive review of GHB, GBL, and 1,4-BD toxicology including epidemiology

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveThis interaction is implicated in multiple fatalities.^[16]62%

Inconclusive

Abstract documents GHB/precursor fatalities in Australasia but does not specifically implicate the ethanol interaction in those deaths.

Study identifying deaths associated with GHB, GBL, and 1,4-BD overdose in Australasia

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveMultiple fatalities in the published literature involve GHB/1,4-BD combined with opioids.^[16]62%

Inconclusive

Abstract identifies GHB/precursor fatalities in Australasia but does not mention opioid co-involvement in the abstract text.

Study identifying deaths associated with GHB, GBL, and 1,4-BD overdose in Australasia

checked by claude-sonnet-4-6 · May 9, 2026

partialMultiple fatalities in the published literature involve GHB/1,4-BD combined with opioids.^[17]72%

Partial

Abstract confirms polydrug use is common in Nordic GHB fatalities, consistent with opioid co-involvement, but opioids are not specifically named.

polydrug use common

checked by claude-sonnet-4-6 · May 9, 2026

verifiedAdditive CNS and respiratory depression at intoxicating doses^[40]93%

Verified

Abstract confirms GHB causes collapse, convulsions, and coma aggravated by alcohol and benzodiazepines, directly supporting additive CNS depression.

GHB causes collapse, convulsions, coma aggravated by alcohol and benzodiazepines

checked by claude-sonnet-4-6 · May 9, 2026

verifiedAdditive CNS and respiratory depression at intoxicating doses^[41]95%

Verified

Abstract directly confirms respiratory depression and coma at high doses and cross-depressant effects with other CNS drugs.

respiratory depression and coma at high doses; cross-depressant with other CNS drugs

checked by claude-sonnet-4-6 · May 9, 2026

partialBarbiturates, sedative-hypnotics, antipsychotics, and ketamine all carry risk of additive CNS depression when combined with 1,4-BD.^[40]75%

Partial

Abstract confirms additive CNS depression with alcohol and benzodiazepines, but barbiturates, antipsychotics, and ketamine are not mentioned.

GHB causes collapse, convulsions, coma aggravated by alcohol and benzodiazepines

checked by claude-sonnet-4-6 · May 9, 2026

verifiedIn rats, diclofenac reduced brain GHB concentrations and attenuated respiratory depression^[29]99%

Verified

Abstract directly confirms diclofenac reduces brain GHB concentration and respiratory depression in rats via MCT1 inhibition.

Diclofenac (NSAID) inhibits MCT1-mediated GHB transport into brain, reducing brain GHB concentration and respiratory depression in rats

checked by claude-sonnet-4-6 · May 9, 2026

verifiedIn chemsex contexts, GHB/GBL/1,4-BD is frequently combined with antiretroviral medications containing CYP3A4/P-gp inhibitors (ritonavir, cobicistat)^[42]97%

Verified

Abstract directly confirms chemsex GHB/GBL use in an HIV clinic and specifically names ritonavir/cobicistat-containing antiretrovirals as a drug-interaction concern.

Prevalence of chemsex including GHB/GBL in HIV clinic; concern about drug-drug interactions between chemsex drugs and ritonavir/cobicistat-containing antiretrovirals

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveConcurrent ethanol use: Risk of profound, unpredictable, and potentially lethal CNS depression through the dual ADH competition and synergistic depression mechanism.^[13]65%

Inconclusive

Abstract is a comprehensive toxicology review that would cover this interaction but the specific mechanistic risk characterization is not in the abstract text.

Comprehensive review of GHB, GBL, and 1,4-BD toxicology including epidemiology, mechanisms, toxicokinetics

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveConcurrent ethanol use: Risk of profound, unpredictable, and potentially lethal CNS depression through the dual ADH competition and synergistic depression mechanism.^[16]62%

Inconclusive

Abstract identifies GHB/precursor fatalities in Australasia but does not specifically attribute or describe the ethanol-ADH mechanism.

Study identifying deaths associated with GHB, GBL, and 1,4-BD overdose in Australasia

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveConcurrent opioid use: Additive respiratory depression; multiple documented fatalities.^[16]62%

Inconclusive

Abstract documents fatalities from GHB/precursors in Australasia but does not specifically mention opioid co-use or additive respiratory depression.

Study identifying deaths associated with GHB, GBL, and 1,4-BD overdose in Australasia

checked by claude-sonnet-4-6 · May 9, 2026

partialConcurrent opioid use: Additive respiratory depression; multiple documented fatalities.^[17]72%

Partial

Abstract confirms polydrug fatalities in Nordic countries (supporting 'multiple documented fatalities'), but opioids are not specifically named.

GHB found in fatal poisoning cases across all five Nordic countries; polydrug use common

checked by claude-sonnet-4-6 · May 9, 2026

verifiedConcurrent benzodiazepine or sedative-hypnotic use: Additive CNS depression at intoxicating doses.^[40]95%

Verified

Abstract directly confirms GHB-induced coma is aggravated by benzodiazepines, confirming additive CNS depression.

GHB causes collapse, convulsions, coma aggravated by alcohol and benzodiazepines

checked by claude-sonnet-4-6 · May 9, 2026

verifiedConcurrent benzodiazepine or sedative-hypnotic use: Additive CNS depression at intoxicating doses.^[41]95%

Verified

Abstract confirms cross-depressant effects with other CNS drugs, directly supporting additive CNS depression with sedative-hypnotics.

cross-depressant with other CNS drugs; abuse/dependence/withdrawal risk

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveActive respiratory compromise: GHB produces dose-dependent respiratory depression; pre-existing respiratory insufficiency increases overdose risk.^[13]65%

Inconclusive

Abstract covers clinical features in a comprehensive toxicology review but the specific contraindication for pre-existing respiratory compromise is not in the abstract text.

Comprehensive review of GHB, GBL, and 1,4-BD toxicology including... clinical features

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveOperating vehicles or machinery: Motor impairment, sedation, and amnesia preclude safe operation.^[13]60%

Inconclusive

Abstract covers GHB/1,4-BD toxicology but does not specifically address driving or machinery operation risks in the abstract text.

Comprehensive review of GHB, GBL, and 1,4-BD toxicology including epidemiology, mechanisms, toxicokinetics, clinical features

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveEpilepsy or seizure history: GHB can modulate seizure threshold, and withdrawal precipitates seizures.^[13]65%

Inconclusive

Abstract covers clinical features and withdrawal in a comprehensive review but does not specifically address seizure threshold modulation or epilepsy as a contraindication in the abstract text.

Comprehensive review of GHB, GBL, and 1,4-BD toxicology including... clinical features, management, and withdrawal

checked by claude-sonnet-4-6 · May 9, 2026

verifiedADH1B variant carriers: Unpredictably slow 1,4-BD conversion creates risk of delayed, extended, or paradoxically intense intoxication.^[8]88%

Verified

Abstract confirms ADH1B G143A variant is associated with slower metabolism; delayed, extended, or intense intoxication from slower conversion is a direct and reasonable clinical inference.

ADH-IB G143A variant associated with slower metabolism

checked by claude-sonnet-4-6 · May 9, 2026

verifiedNSAID use (particularly diclofenac): Potential alteration of GHB brain distribution via MCT1 inhibition; clinical significance unclear.^[29]97%

Verified

Abstract directly confirms diclofenac inhibits MCT1-mediated GHB transport into brain and notes NSAIDs may modulate GHB pharmacodynamics.

Diclofenac (NSAID) inhibits MCT1-mediated GHB transport into brain; NSAIDs may modulate GHB pharmacodynamics

checked by claude-sonnet-4-6 · May 9, 2026

verifiedPlasma GHB concentrations of approximately 100 mg/L produce euphoria and disinhibition, while concentrations approaching 500 mg/L have been associated with fatal cardiorespiratory depression — a five-fold range defining a dangerously narrow therapeutic-to-lethal window.^[7]97%

Verified

Abstract directly confirms the ~100 mg/L and ~500 mg/L concentration-effect thresholds. The five-fold calculation is mathematically correct and the 'narrow window' characterization is consistent with the data.

~100 mg/L plasma GHB causes euphoria/disinhibition; ~500 mg/L can cause death

checked by claude-sonnet-4-6 · May 9, 2026

comparative pharmacology7 claims4verified1partial2inconclusive

partialBaclofen has been used therapeutically to manage GHB/1,4-BD withdrawal, leveraging GABA-B agonism to substitute for the missing GHB stimulus.^[32]75%

Partial

Abstract provides animal study evidence supporting GABA-B agonist baclofen for GHB withdrawal, confirming the pharmacological rationale, but 'therapeutically used' implies human clinical use that this abstract (animal studies only) does not directly confirm.

Animal studies support GABA-B agonist baclofen as more effective strategy for GHB withdrawal than benzodiazepines

checked by claude-sonnet-4-6 · May 9, 2026

verifiedBaclofen has been used therapeutically to manage GHB/1,4-BD withdrawal, leveraging GABA-B agonism to substitute for the missing GHB stimulus.^[33]95%

Verified

Abstract is a human case report of GHB withdrawal resolved with baclofen, directly confirming therapeutic use.

Case report: 11-day hospitalization for GHB withdrawal, resolved with baclofen as novel adjunct after usual supportive treatment

checked by claude-sonnet-4-6 · May 9, 2026

inconclusiveGBL users may face higher dependence risk than direct GHB users owing to GBL's more rapid absorption producing sharper peak GHB concentrations and a stronger reinforcement signal. 1,4-BD's risk profile differs from both: its slower conversion produces a more gradual onset (lower peak reinforcement per dose), but its longer duration means sustained receptor occupancy, potentially elevating physical dependence risk with repeated dosing.^[5]65%

Inconclusive

Abstract covers addiction potential of GHB and precursors but does not contain the specific comparative risk analysis between GBL, GHB, and 1,4-BD users.

Review of neurochemistry, acute toxicity, addiction potential, withdrawal, and treatment of GHB and its precursors

checked by claude-sonnet-4-6 · May 9, 2026

Inconclusive

Duplicate citation for the same claim. Abstract covers addiction potential but not the specific comparative risk profiles between GBL, GHB, and 1,4-BD.

Review of neurochemistry, acute toxicity, addiction potential, withdrawal, and treatment of GHB and its precursors

checked by claude-sonnet-4-6 · May 9, 2026

verifiedIn discriminative stimulus studies in rats, both GHB and 1,4-BD fully substitute for baclofen, confirming identical receptor mechanisms^[22]97%

Verified

Abstract confirms >80% baclofen-lever responding for both GHB and 1,4-BD, confirming shared GABA-B mechanism.

GHB and 1,4-BD occasioned >80% baclofen-lever responding, confirming GABA-B primary mechanism

checked by claude-sonnet-4-6 · May 9, 2026

verifiedThe key pharmacological distinction is that 1,4-BD produces a consistently longer duration of action than equi-effective GHB doses, attributable to the rate-limiting ADH conversion step.^[10]95%

Verified

Abstract directly confirms 1,4-BD has longer duration of action than GHB; the ADH rate-limiting mechanism is a reasonable inference from the same study.

Showed 1,4-BD has similar onset but longer duration of action than GHB

checked by claude-sonnet-4-6 · May 9, 2026

verifiedBrain Fos mapping demonstrates that GHB uniquely activates the median raphe nucleus and lateral habenula, regions not activated by baclofen.^[25]99%

Verified

Abstract directly confirms unique activation of raphe nucleus and lateral habenula by GHB compared to baclofen.

unique activation of raphe nucleus and lateral habenula. GHB has prosocial, euphoric effects not shared by baclofen

checked by claude-sonnet-4-6 · May 9, 2026

Coverage & Gaps

effect links

83 links · 83 approved · 0 audited0/83 with evidence basis

Research Trail

substance-article pipeline-v5 May 9, 2026

Step	Source	Query	Results
1database lookup	PubChem	1,4-Butanediol	1 result, 1 selected
selection rationaleselection rationale Primary chemical identity data — confirms molecular formula, weight, InChIKey
2literature search	PubMed	1,4-butanediol pharmacology GHB metabolism mechanism	9 results, 8 selected
selection rationaleselection rationale All directly relevant to 1,4-BD pharmacology, mechanism of action, and metabolism
3literature search	PubMed	1,4-butanediol toxicity overdose case report	1 result, 1 selected
selection rationaleselection rationale Key case report highlighting unique pharmacokinetic features of 1,4-BD overdose vs GHB
4literature search	OpenAlex	1,4-butanediol GHB precursor pharmacology	10 results, 6 selected
selection rationaleselection rationale Most-cited landmark papers on GHB/1,4-BD pharmacology, toxicology, and transport
5literature search	PubMed	GHB scheduling controlled substance regulation United States DEA	1 result, 1 selected
selection rationaleselection rationale Relevant to regulatory context for GHB precursors
6literature search	PubMed	GHB GABA-B receptor binding affinity Ki EC50	0 results, 0 selected
selection rationaleselection rationale Broadened to GABAergic mechanism search
7literature search	PubMed	GHB receptor binding GABA-B agonist baclofen pharmacology CNS depressant	8 results, 6 selected
selection rationaleselection rationale Direct receptor binding data and mechanism of action studies
8literature search	PubMed	1,4-butanediol alcohol dehydrogenase conversion GHB metabolism ethanol interaction	1 result, 1 selected
selection rationaleselection rationale Key metabolic pathway paper
9literature search	PubMed	fomepizole treatment 1,4-butanediol GHB antidote alcohol dehydrogenase inhibitor	2 results, 2 selected
selection rationaleselection rationale Key papers establishing antidote mechanism and ADH role
10literature search	PubMed	GHB narcolepsy cataplexy sodium oxybate Xyrem FDA clinical use	6 results, 3 selected
selection rationaleselection rationale History of GHB discovery (1960), schedule I/III legal framework, therapeutic uses
11web search	WebSearch	1,4-butanediol legal status scheduling UK US EU Australia controlled substance 2024	10 results, 3 selected
selection rationaleselection rationale Legal status across major jurisdictions - needed as fallback to structured APIs
12web search	WebSearch	1,4-butanediol DEA controlled substance analog act United States scheduling history	9 results, 0 selected
selection rationaleselection rationale US legal framework clarification
13web search	WebSearch	1,4-butanediol SMILES CAS number industrial chemical	10 results, 0 selected
selection rationaleselection rationale Chemical identity data and industrial context
14document retrieval	DEA PDF	—	0 results, 0 selected
selection rationaleselection rationale Attempted DEA document retrieval, unsuccessful
15literature search	OpenAlex	GHB tolerance dependence mechanism GABA receptor downregulation	8 results, 3 selected
selection rationaleselection rationale Key papers on GHB/1,4-BD dependence mechanisms and interaction risks
16literature search	OpenAlex	GHB overdose management emergency supportive care	6 results, 3 selected
selection rationaleselection rationale Overdose management and context for GHB as date-rape drug
17web search	WebSearch	1,4-butanediol Canada CDSA schedule 2024	10 results, 0 selected
selection rationaleselection rationale Legal gap for Canada
18web search	WebSearch	GHB 1,4-butanediol Germany Netherlands EU legal status 2024	10 results, 0 selected
selection rationaleselection rationale EU legal landscape for 1,4-BD
19document retrieval	WebFetch	—	1 result, 1 selected
selection rationaleselection rationale EU-level regulatory context for 1,4-BD
20database lookup	Crossref	DOI 10.2174/1570159x13666141210215423	1 result, 1 selected
selection rationaleselection rationale DOI verification for key GHB review paper

Research document (raw, unedited pipeline output)

# Research Output: 1,4-Butanediol (PSX-0002)

---

## Chemical Identity

**Verified from PubChem CID 8064:**

| Property | Value | Source |
|---|---|---|
| PubChem CID | 8064 | [Ref 1 — PubChem] |
| IUPAC name | butane-1,4-diol | [Ref 1] |
| Molecular formula | C₄H₁₀O₂ | [Ref 1] |
| Molecular weight | 90.12 g/mol | [Ref 1] |
| InChIKey | WERYXYBDKMZEQL-UHFFFAOYSA-N | [Ref 1] |
| SMILES | OCCCCO | [Ref 2 — web/Sigma-Aldrich/ChemicalBook] |
| CAS number | 110-63-4 | [Ref 2] |
| Physical state | Colorless, viscous, water-miscible liquid | [Ref 2] |
| Melting point | 16 °C | [Ref 2] |
| Boiling point | 230 °C | [Ref 2] |

**Discrepancies vs. brief seed data:**
- The brief listed no CID, formula, MW, SMILES, or InChIKey. All are now confirmed from PubChem (CID 8064) and chemical sources.
- Slug in DB is "1-4-butanediol"; standard IUPAC is butane-1,4-diol; CAS 110-63-4 is widely used in industrial contexts.

**Stereochemistry:** 1,4-Butanediol has no chiral center; it is an achiral linear diol. No active isomers.

**Industrial context:** 1,4-BD is a major commodity chemical used in the production of tetrahydrofuran (THF), spandex fibers, polyurethanes, and as an industrial solvent [Ref 2]. Its dual industrial/recreational status is central to regulatory complexity.

---

## Pharmacology

### Mechanism of Action

1,4-BD is a **prodrug** — it is pharmacologically inert until metabolically converted to gamma-hydroxybutyric acid (GHB) by the enzyme **alcohol dehydrogenase (ADH)** in a two-step oxidation: 1,4-BD → 4-hydroxybutyraldehyde → GHB (the second step catalyzed by aldehyde dehydrogenase, ALDH) (Lenz et al. 2011 [Ref 10]). This conversion has been conclusively confirmed in human liver cytosolic preparations (Lenz et al. 2011 [Ref 10]) and in living humans (Thai et al. 2007 [Ref 19]; Liakoni et al. 2019 [Ref 32]).

Once converted, GHB acts via two receptor systems:

**1. GABA-B receptor (primary mechanism):**
- GHB is a weak partial agonist at GABA-B receptors with Ki ≈ 100 µM (Mathivet et al. 1997 [Ref 22]) and EC50 ≈ 5 mM at recombinant GABA-B1/B2 in Xenopus oocytes, achieving ~69% of maximal baclofen response (Lingenhoehl et al. 1999 [Ref 21]).
- Despite this weak affinity, GABA-B receptors mediate GHB's primary behavioral and pharmacological effects. GABA-B1 knockout mice lose all pharmacological effects of GHB (hypolocomotion, hypothermia, dopamine synthesis increases, delta-wave induction) while retaining GHB-specific binding sites (Kaupmann et al. 2003 [Ref 24]).
- GABA-B antagonists (CGP 35348, SCH 50911, CGP 46381) completely antagonize GHB sedation, ataxia, and discriminative stimulus effects (Carai et al. 2001 [Ref 25]; Carter et al. 2003 [Ref 4]; Carter et al. 2004 [Ref 5]).
- In rats discriminating baclofen (GABA-B agonist), GHB and 1,4-BD both occasion >80% baclofen-lever responding, confirming GABA-B as the primary discriminative mechanism (Carter et al. 2004 [Ref 5]).
- Chronic GHB treatment produces cross-tolerance to baclofen but NOT to benzodiazepines (flunitrazepam), indicating GABA-B selectivity in tolerance development (Smith et al. 2006 [Ref — not indexed but see Kamal 2016 Ref 36]).

**2. GHB-specific receptor (distinct from GABA-B):**
- Evidence supports a distinct, G-protein coupled presynaptic GHB receptor separate from GABA-B. GHB decreases forskolin-stimulated cAMP in cortex and hippocampus but not thalamus or cerebellum — a different distribution from baclofen — and this effect is blocked by GHB-specific antagonists (NCS-382) but not GABA-B antagonists (Snead 2000 [Ref 23]).
- The GHB-specific receptor may underlie prosocial effects, euphoria, and narcolepsy therapeutic benefit not shared by baclofen (van Nieuwenhuijzen et al. 2009 [Ref 26]).
- Brain Fos mapping shows GHB uniquely activates the median raphe nucleus and lateral habenula (not seen with baclofen), as well as sleep-wake nuclei at higher doses (van Nieuwenhuijzen et al. 2009 [Ref 26]).
- High-affinity GHB binding site Kd ≈ 95 nM; low-affinity site Kd ≈ 16 µM (Tunnicliff 1992 [Ref 27]).

**Dopaminergic modulation:** GHB modulates dopamine release in the mesolimbic system (substantia nigra/nucleus accumbens), contributing to euphoric and addiction-related properties (Tunnicliff 1992 [Ref 27]; Kamal et al. 2016 [Ref 36]).

**Other systems affected:** Serotonin, norepinephrine, cholinergic systems, neurosteroidogenesis, and oxytocin release are all modulated by chronic GHB/1,4-BD exposure (Kamal et al. 2016 [Ref 36]).

### Pharmacokinetics (1,4-BD specific)

**Reference study:** Thai et al. (2007) [Ref 19] — the only published controlled human pharmacokinetic study specifically examining 1,4-BD. Design: double-blind, placebo-controlled crossover, n=8 healthy volunteers, single oral dose 25 mg/kg.

| Parameter | 1,4-BD | GHB (from 1,4-BD) |
|---|---|---|
| Tmax | 24 ± 12 min | 39.4 ± 11.2 min |
| T1/2 (elimination) | 39.3 ± 11 min | 32.3 ± 6.6 min |
| Cmax | N/A | 45.6 ± 19.7 mg/L |
| Oral clearance (CL/F) | 598.8 ± 446.6 mL/min·kg (wild-type ADH) | — |

**ADH1B genetic variability:** Subjects with variant ADH1B G143A haplotype showed markedly slower 1,4-BD clearance (CL/F 151.5 vs 598.8 mL/min·kg, p=0.061), predicting significant inter-individual variability in GHB conversion rate and peak effect (Thai et al. 2007 [Ref 19]).

**Note:** At 25 mg/kg dose (Thai 2007 [Ref 19]), subjects reported only mild cognitive effects (less alert, reduced concentration, lightheadedness). Recreational doses are estimated to be significantly higher.

**Comparison with direct GHB pharmacokinetics** (Brenneisen et al. 2004 [Ref 39], n=8, 25 mg/kg oral GHB):
- Tmax: 20–45 min; T1/2: 30.4 ± 2.45 min; Vd: 52.7 ± 15.0 L
- Only 1.2% of dose excreted unchanged in urine; detection window: ~12 h urine, ~6 h oral fluid
- GHB rapidly converted to GBL at first pass and distributed to all tissues

**1,4-BD produces longer duration of action than GHB:** When 1,4-BD is compared directly to GHB in discriminative stimulus studies, the onset of action is similar but 1,4-BD exhibits a consistently **longer duration** — attributed to the rate-limiting conversion step (Carter et al. 2003 [Ref 4]).

**GBL and 1,4-BD conversion to GHB:** GBL and 1,4-BD are both rapidly converted to GHB in vivo; t1/2 of conversion is approximately 1 minute for GBL (Busardò & Jones 2014 [Ref 20]). 1,4-BD conversion is slower due to the two-step ADH/ALDH pathway. Cmax for GHB occurs within 20–40 min after precursor ingestion (Busardò & Jones 2014 [Ref 20]).

**Blood-brain barrier transport:** GHB crosses the BBB via monocarboxylate transporters (MCT isoforms — high-capacity, low-affinity: Vmax ~709 nmol/min/g, Km ~11 mM), not passive diffusion (Bhattacharya & Boje 2004 [Ref 7]).

**Concentration-effect relationship for GHB** (directly applicable to 1,4-BD as prodrug):
- ~100 mg/L plasma GHB → euphoria, disinhibition (Busardò & Jones 2014 [Ref 20])
- ~500 mg/L plasma GHB → potentially fatal cardiorespiratory depression (Busardò & Jones 2014 [Ref 20])
- Steep concentration-effect curve; narrow therapeutic/toxicological window

### Metabolic Pathway & CYP Involvement

The 1,4-BD → GHB conversion is mediated by **ADH** (confirmed in human liver in vitro: Lenz et al. 2011 [Ref 10]; in humans in vivo: Liakoni et al. 2019 [Ref 32]; Kapadia et al. 2007, rat in vivo: [Ref 33]). The second step (aldehyde → GHB) involves ALDH. CYP enzyme involvement has not been established for this pathway; there is no published evidence for significant CYP contribution to 1,4-BD metabolism. GHB itself is eliminated via the TCA cycle (converted to succinic acid) without major CYP involvement (Felmlee et al. 2021 [Ref 11]).

---

## History

**GHB synthesis and discovery:**
GHB was first synthesized by Henri Laborit in 1960, working at the Institut Biomédical des Cordeliers in Paris, as part of research into GABA derivatives that could cross the blood-brain barrier (Fuller & Hornfeldt 2004 [Ref 34]). It was initially developed and used as a general anesthetic. By the 1970s, GHB's endogenous presence in the mammalian brain was established, and it was studied as a putative neurotransmitter.

**1,4-Butanediol's industrial history predates its recreational use** by decades. It is a bulk commodity chemical synthesized via multiple industrial routes (e.g., Reppe chemistry). Its recreational use emerged specifically as a consequence of GHB's regulatory history.

**Bodybuilding and unregulated use (1980s–1990s):**
During the 1980s, GHB-containing products became popular in bodybuilding circles for alleged anabolic effects and growth hormone stimulation. Easy access to GHB and its precursors (including 1,4-BD) through unregulated channels led to recreational adoption (Fuller & Hornfeldt 2004 [Ref 34]).

**Club drug era (late 1990s):**
GHB and its precursors became popular at raves and nightclubs for their euphoric and disinhibiting properties. Use as a drug-facilitated sexual assault (DFSA) agent — "date rape drug" — gained notoriety (Varela 2004 [Ref 44]; Scott-Ham & Burton 2005 [Ref in DFSA search]).

**US regulatory history:**
- GHB designated Schedule I in the US in 2000 (Hillory J. Farias and Samantha Reid Date-Rape Drug Prohibition Act of 2000)
- FDA-approved sodium oxybate (Xyrem) placed on Schedule III simultaneously — a unique bifurcated schedule (Fuller & Hornfeldt 2004 [Ref 34])
- FDA approval for narcolepsy/cataplexy: July 2002 (Fuller & Hornfeldt 2004 [Ref 34])
- 1,4-BD: Not individually scheduled; subject to Federal Analogue Act prosecution as a GHB analog if intended for human consumption. Courts ruled 1,4-BD is "substantially similar" to GHB structurally and pharmacologically (web-retrieved legal review [Ref 41])

**Precursors (GBL, 1,4-BD) as regulatory workarounds:**
Once GHB became controlled in the US and Europe, GBL and 1,4-BD emerged as preferred alternatives precisely because they were unregulated industrial chemicals readily available commercially. This pattern has been repeatedly observed in Europe (Brunt et al. 2014 [Ref 2]; Schep et al. 2012 [Ref 1]).

---

## Subjective Effects

The following effects are documented in published literature. All effects are attributable to GHB generated from 1,4-BD conversion, though the delayed and potentially prolonged effect profile of 1,4-BD creates distinct patterns compared to direct GHB use.

**From controlled human study (Thai et al. 2007 [Ref 19], 25 mg/kg oral 1,4-BD):**
- Subjects felt less awake and alert
- Reduced ability to concentrate
- Lightheadedness
- Transient blood pressure increase
- Minor pulse oximetry decrease (mean SpO2 98.5% vs 99.6% placebo, p=0.031)
- No major adverse effects at this dose; clinical symptoms were modest

**From clinical reviews of GHB intoxication (Schep et al. 2012 [Ref 1]; Busardò & Jones 2014 [Ref 20]; Tay et al. 2022 [Ref 12]):**

*Low-moderate doses (euphoric range):*
- Euphoria and cognitive euphoria
- Disinhibition and reduced self-control
- Anxiety suppression / relaxation
- Empathy enhancement and sociability
- Sexual arousal enhancement
- Increased talkativeness and communication
- Music enhancement
- Mild amnesia

*Moderate-high doses (sedating range):*
- Pronounced sedation
- Dizziness and motor control impairment
- Anterograde amnesia (significant)
- Nausea, vomiting
- Respiratory depression (dose-dependent)
- Bradycardia
- Hypothermia
- Myoclonus (involuntary body movements)
- Nystagmus

*Overdose range:*
- Loss of consciousness
- Respiratory arrest
- Coma
- Death (usually in combination with other CNS depressants)

**Duration-of-effect comparison:**
- 1,4-BD has a longer duration of action than equivalent GHB doses due to the rate-limiting ADH conversion step (Carter et al. 2003 [Ref 4]; Schep et al. 2012 [Ref 1]).
- Onset for 1,4-BD: generally 30–60 min (vs. 15–30 min for GHB); peak: longer-duration plateau; total duration is correspondingly extended.
- Ethanol co-ingestion delays onset further by competitively inhibiting ADH, causing 1,4-BD to accumulate. When ethanol is eliminated, rapid GHB conversion can produce a delayed but profound CNS depression (Poldrugo & Snead 1984 [Ref 3]; Lenz et al. 2011 [Ref 10]; Stefani & Roberts 2020 [Ref 9]).

**Dose sensitivity note:** Exact toxic dose ranges are unknown for 1,4-BD specifically. The brief's dose data (0.5–4+ mL) is in mL not mg, which is unusual given that recreational 1,4-BD is typically dosed by weight or volume of a liquid. No published controlled trial has established dose ranges across the recreational spectrum. The brief's duration data (onset 20–60 min, peak 1–2h, total 3–5h) is broadly consistent with the literature, though some sources suggest 1,4-BD may have a somewhat longer duration than pure GHB.

**[FLAG for generation agent]:** Dose data is not confirmed by controlled human studies at recreational dose levels. Thai et al. (2007) used only 25 mg/kg (~1.75g for 70kg person), which at liquid density ~1.0 g/mL corresponds to ~1.75 mL — within the "common" range of the brief's seed data. Duration data is consistent with published accounts but lacks controlled human confirmation at recreational doses.

---

## Safety & Toxicity

### LD50 / Lethal Toxicity

**No published human LD50 data for 1,4-BD.** The brief correctly states "exact toxic dosage is unknown."

For GHB (the active metabolite), plasma concentrations ~500 mg/L have been associated with fatal cardiorespiratory depression (Busardò & Jones 2014 [Ref 20]).

Animal data for 1,4-BD toxicity: not identified in this literature search. Rat studies have used doses up to 120 mg/kg for oxidative stress (Sgaravatti et al. 2009 [Ref 8]) and 250–750 mg/kg for behavioral/striatal studies (Kapadia et al. 2007 [Ref 33]).

### Overdose Clinical Features

**Standard GHB/1,4-BD overdose** (Schep et al. 2012 [Ref 1]):
- CNS depression (most prominent feature)
- Respiratory depression — potentially requiring intubation
- Bradycardia (usually mild, rarely requires pharmacological treatment)
- Hypothermia
- Myoclonus
- Nausea/vomiting (aspiration risk in unconscious patients)
- Generally resolves within 2–6 hours with supportive care

**1,4-BD-specific overdose features** (Stefani & Roberts 2020 [Ref 9]):
- **High anion gap metabolic acidosis (HAGMA)** — not typical of GHB; results from 1,4-BD itself or its intermediary metabolites
- **Elevated osmol gap** — 1,4-BD is an osmotically active alcohol
- These features mimic **toxic alcohol poisoning** (methanol, ethylene glycol), creating diagnostic confusion
- 1,4-BD concentrations in the Stefani (2020) case were the highest reported in published literature at the time of publication
- Diagnosis requires specific laboratory testing for 1,4-BD (not detected on standard drug screens)

**Effect of ethanol co-ingestion** (Poldrugo & Snead 1984 [Ref 3]; Lenz et al. 2011 [Ref 10]; Stefani & Roberts 2020 [Ref 9]):
- Ethanol competitively inhibits ADH, blocking 1,4-BD → GHB conversion (Ki for ethanol ~0.56 mM in human liver in vitro)
- During ethanol co-ingestion, 1,4-BD itself accumulates at higher plasma concentrations
- When ethanol is cleared, rapid conversion of accumulated 1,4-BD produces a delayed, potentially severe GHB surge
- This creates a deceptive pattern: user feels minimal effects initially (ethanol masking), then sudden profound sedation

### Fatalities

Deaths associated with GHB and its precursors (GBL, 1,4-BD) are documented:
- Australasian fatalities series: deaths identified specifically associated with GHB and its precursors (Caldicott et al. 2004 [Ref 14])
- Nordic countries: GHB identified in fatal drug poisoning cases across all five Nordic countries in 2012 (Simonsen et al. 2015 [Ref 46])
- Fatalities typically involve polysubstance use, particularly with alcohol, opioids, or benzodiazepines

### Organ Toxicity

**CNS:** High-dose GHB from 1,4-BD causes oxidative stress and lipid peroxidation in rat cerebral cortex (Sgaravatti et al. 2009 [Ref 8]). Whether this translates to lasting CNS damage in humans requires further study. Cognitive impairment associated with chronic GHB/1,4-BD use has been documented in a systematic review (Amsterdam et al. 2022 [Ref 17]).

**Respiratory:** Dose-dependent respiratory depression is the primary mechanism of death. No specific pulmonary toxicity documented beyond acute depression.

**Hepatic/Renal:** No specific organ toxicity data for 1,4-BD identified beyond metabolic acidosis in overdose (Stefani & Roberts 2020 [Ref 9]).

### Drug-Facilitated Sexual Assault (DFSA)

GHB (and by extension 1,4-BD as prodrug) is used as a DFSA agent owing to:
- Rapid CNS depression causing incapacitation
- Anterograde amnesia preventing victim recall
- Rapid elimination limiting detection window (urine <12h, Brenneisen et al. 2004 [Ref 39])
- Colorlessness and faint taste allowing surreptitious addition to beverages

Documented in UK DFSA cases (Scott-Ham & Burton 2005), European cases (Varela 2004 [Ref 44]), and forensic literature generally. NOTE: population-level evidence suggests alcohol is far more commonly implicated in opportunistic DFSA than GHB (Hagemann et al. 2013 — found in DFSA search, not formally cited); GHB's DFSA reputation may be disproportionate to its actual frequency.

---

## Harm Reduction

### Contraindications (From Literature)

**Absolute contraindications:**
- Co-administration with alcohol: risk of profound synergistic CNS/respiratory depression AND paradoxical interaction (see above). Often implicated in fatal cases (Caldicott et al. 2004 [Ref 14]; Schep et al. 2012 [Ref 1])
- Co-administration with benzodiazepines, opioids, sedative-hypnotics: additive CNS/respiratory depression (Schep et al. 2012 [Ref 1]; Doyno & White 2021 [Ref 38]; Devlin & Henry 2008 [Ref 42])
- Epilepsy or seizure history (GHB/1,4-BD can lower seizure threshold in some contexts and cause seizures on withdrawal)
- Pregnancy (no safety data)
- Respiratory conditions (impairs respiratory drive)
- Operating machinery or driving

**Relative contraindications:**
- ADH variant (ADH1B*2 carriers): unpredictably slow conversion, risk of delayed overdose (Thai et al. 2007 [Ref 19])
- Diclofenac and potentially other NSAIDs: inhibit MCT1 transport of GHB into brain, may alter pharmacodynamics in complex ways (Rodriguez-Cruz et al. 2021 [Ref — PMID 34191301])

### Emergency Response

Management of 1,4-BD/GHB overdose is **supportive** (Schep et al. 2012 [Ref 1]; Mégarbane et al. 2020 [Ref 43]):
- Airway protection (most critical — prone to aspiration due to vomiting and loss of consciousness)
- Supplemental oxygen
- Assisted ventilation / intubation if respiratory depression
- Monitor cardiac rhythm (bradycardia, though rarely intervention-required)
- Recovery typically occurs within 2–6 hours

**Fomepizole (4-methylpyrazole) as antidote:**
- Fomepizole (ADH inhibitor) has been confirmed in humans to block 1,4-BD → GHB conversion, reducing GHB exposure (Liakoni et al. 2019 [Ref 32])
- **Paradoxical consideration:** Blocking conversion allows 1,4-BD to accumulate; 1,4-BD itself appears to have CNS and cardiovascular effects (blood pressure lowering) (Liakoni et al. 2019 [Ref 32]). Clinical use requires careful benefit-risk assessment.
- In the Stefani (2020) [Ref 9] case, IV ethanol and haemodiafiltration were used.

**No specific pharmacological antidote exists** for GHB intoxication analogous to naloxone for opioids (Busardò & Jones 2014 [Ref 20]).

### Testing and Identification

- 1,4-BD is not detected by standard commercial drug immunoassay screens
- Gas chromatography-mass spectrometry (GC-MS) is required for specific identification (Brenneisen et al. 2004 [Ref 39])
- In overdose, 1,4-BD may be identified by osmol gap and HAGMA before specific laboratory confirmation (Stefani & Roberts 2020 [Ref 9])
- GHB endogenous levels complicate low-level detection in forensic cases

---

## Tolerance & Dependence

### Tolerance Development

Tolerance to GHB/1,4-BD develops with regular use and appears to be **GABA-B receptor mediated**:
- Chronic GHB treatment in rats produces cross-tolerance to baclofen (GABA-B agonist) but NOT to flunitrazepam (GABA-A), demonstrating GABA-B receptor-specific tolerance (Kamal et al. 2016 [Ref 36])
- This selective GABA-B tolerance means standard benzodiazepine doses are relatively ineffective for withdrawal — a critical clinical implication
- Tolerance development rate in humans: within several weeks of continuous use (DB seed data, consistent with clinical literature)
- The brief states "full reset: 10.5 days" — this figure was not confirmed in published literature; no controlled human study on 1,4-BD tolerance reset timeline was found. This appears to be extrapolated from community consensus or GHB data.

**[FLAG for generation agent]:** Tolerance reset duration of "10.5 days" not confirmed in published sources. Requires community evidence or analog inference label.

### Dependence Liability

GHB and its precursors (including 1,4-BD) are highly physically and psychologically addictive (Brunt et al. 2014 [Ref 2]). The neurobiological basis is complex:
- Chronic exposure affects GABA-B, GABA-A (β1-subunit), glutamate, dopamine, serotonin, norepinephrine, cholinergic systems, neurosteroidogenesis, and oxytocin (Kamal et al. 2016 [Ref 36])
- Dutch data: GHB dependence treatment admissions increased sharply in the Netherlands (Kamal et al. 2016 [Ref 36])
- GBL users may be at higher risk than GHB users due to GBL's more rapid absorption and higher peak GHB concentrations; 1,4-BD may have similar risk elevation due to longer duration (Brunt et al. 2014 [Ref 2])

### Withdrawal Syndrome

GHB/1,4-BD withdrawal is **clinically comparable to alcohol and benzodiazepine withdrawal** but with faster onset due to GHB's short half-life (Schep et al. 2012 [Ref 1]; Moitroux & Kestens 2023 [Ref — PMID 37560960]):

**Features (Schep et al. 2012 [Ref 1]):**
- Anxiety, agitation, irritability
- Insomnia
- Tremors
- Tachycardia, hypertension
- Auditory and visual hallucinations
- Sweating
- Delirium (potentially rapid onset — faster than alcohol withdrawal)
- Seizures
- Rhabdomyolysis (Borelli et al. 2025 [Ref 28])
- Duration: typically 5–7 days; severe cases may persist longer; one case documented recurrence over 56 days (Gupta et al. 2025 [Ref — PMID 39021043])

**Clinical management challenge:** Benzodiazepines are first-line but show high treatment resistance (Brunt et al. 2014 [Ref 2]; Siefried et al. 2023 [Ref 16]). This reflects the GABA-B vs GABA-A tolerance selectivity.

**Treatment options:**
- High-dose benzodiazepines (first line, but limited efficacy in severe cases) (Schep et al. 2012 [Ref 1])
- Baclofen (GABA-B agonist — pharmacological rationale, LeTourneau et al. 2008 [Ref 30]; Lai et al. 2022 [Ref 35 — PMID 35812608])
- Phenobarbital (barbiturate — GABA-A mechanism, for severe benzodiazepine-resistant cases: Freeman et al. 2023 [Ref 29])
- Titration and tapering with pharmaceutical GHB (sodium oxybate) — used in Netherlands, shown effective (Brunt et al. 2014 [Ref 2]; Tay et al. 2022 [Ref 12])
- Propofol, in ICU for most severe cases

**High relapse rates** documented; limited evidence for long-term maintenance therapy (Brunt et al. 2014 [Ref 2]).

---

## Interactions

### Critical Interactions (Life-Threatening)

**1. Ethanol (alcohol):**
- Mechanism A (synergistic CNS depression): Both GHB and ethanol are CNS depressants; combination produces greater-than-additive respiratory depression and risk of fatal overdose (Poldrugo & Snead 1984 [Ref 3]; Schep et al. 2012 [Ref 1])
- Mechanism B (ADH competition): Ethanol competitively inhibits ADH, blocking 1,4-BD → GHB conversion; this delays and then intensifies GHB's effects when ethanol clears (Lenz et al. 2011 [Ref 10]; Poldrugo & Snead 1984 [Ref 3]; Stefani & Roberts 2020 [Ref 9])
- Net result: unpredictable and potentially lethal delayed CNS depression
- Severity: **SEVERE — avoid entirely**

**2. Opioids:**
- Additive CNS and respiratory depression
- Multiple fatalities in the literature involve GHB/1,4-BD + opioid combinations (Caldicott et al. 2004 [Ref 14]; Simonsen et al. 2015 [Ref 46])
- Severity: **SEVERE — contraindicated**

**3. Benzodiazepines:**
- Additive CNS and respiratory depression (Devlin & Henry 2008 [Ref 42]; Doyno & White 2021 [Ref 38])
- Particularly dangerous in combination at intoxicating doses
- Severity: **SEVERE — contraindicated**

**4. Other CNS depressants** (barbiturates, sedative-hypnotics, antipsychotics, ketamine, etc.):
- Class effect: additive CNS depression
- Severity: **SIGNIFICANT — strongly cautioned against**

### Other Interactions

**Diclofenac / NSAIDs:**
- Inhibit monocarboxylate transporters (MCT1) that transport GHB across the blood-brain barrier and in renal tubules
- Diclofenac reduced brain GHB concentrations and respiratory depression in rats (Rodriguez-Cruz et al. 2021 [Ref — PMID 34191301])
- Potential for altered GHB pharmacodynamics; clinical significance unclear in recreational context

**Antiretroviral drugs (ritonavir, cobicistat):**
- Chemsex context: ritonavir/cobicistat (CYP3A4/P-gp inhibitors) combined with GHB/GBL in HIV-positive MSM — potential for drug-drug interactions (Adler et al. 2022 [Ref — PMID 35048490])
- Clinical significance for 1,4-BD specifically: not well characterized, but relevant to chemsex harm reduction

**Serotonin syndrome risk:** No evidence for serotonin syndrome risk with 1,4-BD/GHB found in the literature searched. Not a documented interaction of concern.

### Social/Contextual Use Patterns

GHB/GBL/1,4-BD are used prominently in **chemsex** among men who have sex with men (MSM), often in combination with methamphetamine, mephedrone, and other substances (Giorgetti et al. 2017 [Ref — OpenAlex]; Tay et al. 2022 [Ref 12]). This polysubstance context significantly amplifies interaction risks.

---

## Legal Status

| Jurisdiction | Status | Notes |
|---|---|---|
| **United States** | Not scheduled under the CSA | Subject to Federal Analogue Act prosecution if intended for human consumption — courts have upheld GHB-analog status. GHB itself is Schedule I (Schedule III for Xyrem). GBL: List I chemical (DEA) [Ref 31] |
| **United Kingdom** | Class C (Misuse of Drugs Act 2009) | Exception: industrial import/export/supply exempt unless *knowing or believing* it will be used for human ingestion [Ref 41] |
| **Australia** | Border-controlled drug (since March 2024) | Up to life imprisonment for illegal importation. AFP enforcement increasing [Ref 41] |
| **France** | Banned since September 2, 2011 | Sale/supply of raw or >10% concentration, >100 mL product prohibited [Ref 45] |
| **Germany** | Partially regulated; NpSG amendment planned (2025) | Not explicitly scheduled under current NpSG; amendment bill adopted July 2025 cabinet to add GBL/1,4-BD [Ref — web-retrieved] |
| **EU (overall)** | No EU-wide controlled substance scheduling | ANSES (France) proposed EU-wide REACH restriction in 2012; not yet implemented at EU level (2024) [Ref 45] |
| **Netherlands** | Accessible | GBL and 1,4-BD available online from Dutch suppliers per EMCDDA data [Ref — web-retrieved] |
| **Canada** | Status unclear | GHB is Schedule III in Canada under CDSA; 1,4-BD's explicit CDSA scheduling status was not confirmed in this research. **[FLAG for editorial review]** |

---

## Clinical Trials

**Search result:** ClinicalTrials.gov search for "1,4-butanediol GHB" returned **zero registered trials.**

No active, recruiting, or completed clinical trials specifically studying 1,4-BD as an intervention or in a pharmacological context were identified. All clinical pharmacology data (Thai 2007 [Ref 19]; Liakoni 2019 [Ref 32]) was conducted as investigator-led research, not registered trials.

Clinical trials for sodium oxybate (GHB) in narcolepsy are extensive (see Boscolo-Berto et al. 2012 meta-analysis [Ref 35]) but these study GHB directly, not 1,4-BD.

---

## Community Feedback Analysis

The brief's Part A2 (Community Feedback) is **empty**. No community feedback was submitted for this substance.

*No community feedback submitted.*

---

## Gaps & Flags

### Data Gaps (Not Found in Published Sources)

1. **Human LD50 / toxic dose range for 1,4-BD specifically:** No published data. Only GHB plasma concentration estimates (~500 mg/L for potentially fatal effects) are available.

2. **Recreational dose-response data:** Thai et al. (2007) studied only 25 mg/kg (1.75 mL equivalent). No human study covers the light-to-heavy recreational dose range. The brief's dose data (0.5–4+ mL) appears derived from community consensus, not controlled studies.

3. **Tolerance reset timeline ("10.5 days"):** Not confirmed in any published source. This figure was not found in the literature. Should be labeled as community consensus or analog estimate in article prose.

4. **Canadian legal status (1,4-BD specifically):** GHB is Schedule III in Canada, but 1,4-BD's CDSA status could not be confirmed.

5. **Long-term neurotoxicity in humans from 1,4-BD specifically:** Only animal data (Sgaravatti 2009 [Ref 8]) and general GHB cognitive impairment data (Amsterdam et al. 2022 [Ref 17]) available.

6. **SMILES was not returned by PubChem API** (only CID, formula, MW, InChIKey returned). SMILES (OCCCCO) verified via web sources (ChemicalBook, Sigma-Aldrich).

### Safety-Critical Flags

1. **Ethanol interaction:** Dual mechanism (synergistic depression + ADH competition causing delayed GHB surge from accumulated 1,4-BD). Particularly severe and counterintuitive. Generation agent should prominently flag this.

2. **Osmol gap / metabolic acidosis in overdose:** 1,4-BD overdose can mimic toxic alcohol poisoning (HAGMA + osmol gap — Stefani 2020 [Ref 9]), potentially leading to inappropriate treatment. Emergency physicians and harm reduction materials should include this.

3. **Delayed onset with ethanol co-ingestion:** Users often misjudge dose because effects are initially blunted by ethanol, then 1,4-BD converts rapidly when ethanol clears — leading to sudden, unexpected overdose.

4. **ADH1B genetic variability:** ~50% of subjects in Thai (2007) had variant ADH1B associated with 4× slower clearance. This predicts high individual variability in response to the same dose.

5. **Withdrawal severity:** GHB/1,4-BD withdrawal can be life-threatening and may progress rapidly to delirium. Unlike opioids, there is no approved reversal agent and withdrawal management remains poorly standardized.

### Source Quality Notes

- All pharmacological mechanism data (receptor binding, discriminative stimulus, GABA-B knockout) derives from animal studies. Human data is limited to the Thai (2007) [Ref 19] and Liakoni (2019) [Ref 32] pharmacokinetic crossover studies.
- Duration and dose data in the brief seed is broadly consistent with published literature but lacks human clinical confirmation at recreational doses.
- Chemsex epidemiology data applies to GHB/GBL as a class; 1,4-BD-specific prevalence data was not found.

1,4-Butanediol

Value Provenance

Dosing

oraltrace →

Duration

oral

Safety

Toxicity Profiletrace →

Dependence Profiletrace →

Withdrawal Profiletrace →

Tolerance Profiletrace →

Effects & Profile

Contraindications

Timeline Phases

oral

Dose Tier Summaries

History

Sources

Claim Verification

Coverage & Gaps

Research Trail

oraltrace

Toxicity Profiletrace

Dependence Profiletrace

Withdrawal Profiletrace

Tolerance Profiletrace